CardioTeca CardioTeca CardioTeca CardioTeca
ESPACIO Síndrome coronario crónico

Biblioteca de referencias

Detalles
G
ESPACIO de síndrome coronario crónico › Bloque G › G4

Guías y evidencia

Lo que recomiendan las guías y lo que demuestran los estudios, separando siempre lo aprobado de lo que se investiga.

G4

Todas las fuentes citadas en el ESPACIO, en formato Vancouver, con DOI y PMID verificados, filtrables por tema y descargables para un gestor bibliográfico.

La evidencia en el tiempo: los artículos y guías citados en este ESPACIO, por año (5 anteriores a 1990, fuera del eje)

510152025303540455055606570758022124722332248536192485119101418262420303425347919901995200020052010201520202025
538referencias: 426 artículos y guías, comprobados en PubMed y Crossref, y 112 fichas técnicas138de 2024, 2025 y 202678guías, consensos y declaraciones científicas

La lista se hace sola con lo que citan las páginas de este ESPACIO y se descarga en RIS.

Descargar en RIS (538 referencias)

Artículos y guías en PubMed (424)

  1. Acute and chronic antianginal efficacy of continuous twenty-four-hour application of transdermal nitroglycerin. Steering Committee, Transdermal Nitroglycerin Cooperative Study. Am J Cardiol. 1991;68(13):1263-73. doi:10.1016/0002-9149(91)90229-e · PMID 1951111I1
  2. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990;15(4):827-32. doi:10.1016/0735-1097(90)90282-t · PMID 2407762H5
  3. Agha AM, Pacor J, Grandhi GR, Mszar R, Khan SU, Parikh R, et al. The Prognostic Value of CAC Zero Among Individuals Presenting With Chest Pain: A Meta-Analysis. JACC Cardiovasc Imaging. 2022;15(10):1745-1757. doi:10.1016/j.jcmg.2022.03.031 · PMID 36202453C5
  4. Ahmed-Jushuf F, Foley MJ, Rajkumar CA, Chotai S, Simader FA, Wang D, et al. Ischemia on Dobutamine Stress Echocardiography Predicts Efficacy of PCI: Results From the ORBITA-2 Trial. J Am Coll Cardiol. 2025;85(18):1740-1753. doi:10.1016/j.jacc.2025.02.034 · PMID 40335250C9
  5. Ajabnoor A, Mukhtar A. Effect of trimetazidine on the functional capacity of ischemic heart disease patients not suitable for revascularization: Meta-analysis of randomized controlled trials. PLoS One. 2022;17(2):e0263932. doi:10.1371/journal.pone.0263932 · PMID 35148340I1
  6. Al-Lamee R, Thompson D, Dehbi HM, Sen S, Tang K, Davies J, et al. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. Lancet. 2018;391(10115):31-40. doi:10.1016/S0140-6736(17)32714-9 · PMID 29103656G2
  7. Alexander JH, Wojdyla D, Vora AN, Thomas L, Granger CB, Goodman SG, et al. Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS. Circulation. 2020;141(20):1618-1627. doi:10.1161/CIRCULATIONAHA.120.046534 · PMID 32223444C10
  8. Alexander KP, Weisz G, Prather K, James S, Mark DB, Anstrom KJ, et al. Effects of Ranolazine on Angina and Quality of Life After Percutaneous Coronary Intervention With Incomplete Revascularization: Results From the Ranolazine for Incomplete Vessel Revascularization (RIVER-PCI) Trial. Circulation. 2016;133(1):39-47. doi:10.1161/CIRCULATIONAHA.115.019768 · PMID 26555329I1
  9. Ali ZA, Landmesser U, Maehara A, Matsumura M, Shlofmitz RA, Guagliumi G, et al. Optical Coherence Tomography-Guided versus Angiography-Guided PCI. N Engl J Med. 2023;389(16):1466-1476. doi:10.1056/NEJMoa2305861 · PMID 37634188C9G2
  10. Alonso JJ, Muñiz J, Gómez-Doblas JJ, Rodríguez-Roca G, Lobos JM, Permanyer-Miralda G, et al. Prevalence of Stable Angina in Spain. Results of the OFRECE Study. Rev Esp Cardiol (Engl Ed). 2015;68(8):691-9. doi:10.1016/j.rec.2014.09.020 · PMID 25697076H2
  11. Amat-Santos IJ, Martin-Yuste V, Fernández-Díaz JA, Martin-Moreiras J, Caballero-Borrego J, Salinas P, et al. Procedural, Functional and Prognostic Outcomes Following Recanalization of Coronary Chronic Total Occlusions. Results of the Iberian Registry. Rev Esp Cardiol (Engl Ed). 2019;72(5):373-382. doi:10.1016/j.rec.2018.05.020 · PMID 29954721G3
  12. Andersen BK, Sejr-Hansen M, Maillard L, Campo G, Råmunddal T, Stähli BE, et al. Quantitative flow ratio versus fractional flow reserve for coronary revascularisation guidance (FAVOR III Europe): a multicentre, randomised, non-inferiority trial. Lancet. 2024;404(10465):1835-1846. doi:10.1016/S0140-6736(24)02175-5 · PMID 39488224C9G2
  13. Andersen BK, Holm NR, Sejr-Hansen M, Erriquez A, Råmunddal T, Stähli BE, et al. Quantitative flow ratio versus fractional flow reserve: 2-year follow-up of the FAVOR III Europe trial. EuroIntervention. 2026;22(9):e489-e498. doi:10.4244/EIJ-D-25-01255 · PMID 42077029C9G2
  14. Andreis A, Imazio M, Piroli F, Avondo S, Casula M, Paneva E, et al. Efficacy and safety of colchicine for the prevention of major cardiovascular and cerebrovascular events in patients with coronary artery disease: a systematic review and meta-analysis on 12 869 patients. Eur J Prev Cardiol. 2022;28(17):1916-1925. doi:10.1093/eurjpc/zwab045 · PMID 33779702C8I1
  15. Ang D, Young R, Taggart D, Carrick D, Chattopadhyay S, Raja Y, et al. International study of coronary microvascular angina (iCorMicA): A registry-based diagnostic study and nested randomized trial. Am Heart J. 2026;301:107527. doi:10.1016/j.ahj.2026.107527 · PMID 42409349G5
  16. Antithrombotic Trialists' (ATT) Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849-60. doi:10.1016/S0140-6736(09)60503-1 · PMID 19482214C10I1
  17. Antman E, Muller J, Goldberg S, MacAlpin R, Rubenfire M, Tabatznik B, et al. Nifedipine therapy for coronary-artery spasm. Experience in 127 patients. N Engl J Med. 1980;302(23):1269-73. doi:10.1056/NEJM198006053022301 · PMID 6767986I1
  18. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation. 2004;110(5):588-636. doi:10.1161/01.CIR.0000134791.68010.FA · PMID 15289388C3C4C7D4H4I1
  19. Arad Y, Spadaro LA, Roth M, Newstein D, Guerci AD. Treatment of asymptomatic adults with elevated coronary calcium scores with atorvastatin, vitamin C, and vitamin E: the St. Francis Heart Study randomized clinical trial. J Am Coll Cardiol. 2005;46(1):166-72. doi:10.1016/j.jacc.2005.02.089 · PMID 15992652C6
  20. Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C, et al. 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J. 2023;44(37):3503-3626. doi:10.1093/eurheartj/ehad194 · PMID 37622657C6I1
  21. Aziz A, Hansen HS, Sechtem U, Prescott E, Ong P. Sex-Related Differences in Vasomotor Function in Patients With Angina and Unobstructed Coronary Arteries. J Am Coll Cardiol. 2017;70(19):2349-2358. doi:10.1016/j.jacc.2017.09.016 · PMID 29096805H3
  22. Bader A, Elsherbini A, An KR, Einstein AJ, Tam DY. ESC vs. ACC/AHA guidelines for non-invasive imaging in chronic coronary disease: guideline discordance, gaps, and future directions. Eur Heart J Cardiovasc Imaging. 2026;27(11):1984-2001. doi:10.1093/ehjci/jeag259 · PMID 42745612G1
  23. Bangalore S, Steg G, Deedwania P, Crowley K, Eagle KA, Goto S, et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308(13):1340-9. doi:10.1001/jama.2012.12559 · PMID 23032550C4
  24. Bangalore S, Guo Y, Samadashvili Z, Blecker S, Xu J, Hannan EL. Revascularization in Patients With Multivessel Coronary Artery Disease and Chronic Kidney Disease: Everolimus-Eluting Stents Versus Coronary Artery Bypass Graft Surgery. J Am Coll Cardiol. 2015;66(11):1209-1220. doi:10.1016/j.jacc.2015.06.1334 · PMID 26361150C6
  25. Bangalore S, Fakheri R, Wandel S, Toklu B, Wandel J, Messerli FH. Renin angiotensin system inhibitors for patients with stable coronary artery disease without heart failure: systematic review and meta-analysis of randomized trials. BMJ. 2017;356:j4. doi:10.1136/bmj.j4 · PMID 28104622C8
  26. Bangalore S, Maron DJ, O'Brien SM, Fleg JL, Kretov EI, Briguori C, et al. Management of Coronary Disease in Patients with Advanced Kidney Disease. N Engl J Med. 2020;382(17):1608-1618. doi:10.1056/NEJMoa1915925 · PMID 32227756C6G2
  27. Bangalore S, Maqsood MH, Zhang RS, Rao SV, Mohamed AE, Christiansen EH, et al. Intracoronary Imaging-Guided Percutaneous Coronary Intervention: An Updated Meta-Analysis of Randomized Trials. J Am Coll Cardiol. 2026. doi:10.1016/j.jacc.2026.08.008 · PMID 42747372C9
  28. Baptista SB, Raposo L, Santos L, Ramos R, Calé R, Jorge E, et al. Impact of Routine Fractional Flow Reserve Evaluation During Coronary Angiography on Management Strategy and Clinical Outcome: One-Year Results of the POST-IT. Circ Cardiovasc Interv. 2016;9(7). doi:10.1161/CIRCINTERVENTIONS.115.003288 · PMID 27412867G3
  29. Barbato E, Gallinoro E, Abdel-Wahab M, Andreini D, Carrié D, Di Mario C, et al. Management strategies for heavily calcified coronary stenoses: an EAPCI clinical consensus statement in collaboration with the EURO4C-PCR group. Eur Heart J. 2023;44(41):4340-4356. doi:10.1093/eurheartj/ehad342 · PMID 37208199C9G1
  30. BARI 2D Study Group, Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360(24):2503-15. doi:10.1056/NEJMoa0805796 · PMID 19502645G2
  31. Bastante T, Arzamendi D, Martín-Moreiras J, Cid-Álvarez AB, ACI-SEC. Spanish cardiac catheterization and coronary intervention registry. 34(th) official report of the Interventional Cardiology Association of the Spanish Society of Cardiology (1990-2024). Rev Esp Cardiol (Engl Ed). 2025;78(11):992-1003. doi:10.1016/j.rec.2025.07.009 · PMID 40914426H2
  32. Bauters C, Deneve M, Tricot O, Meurice T, Lamblin N, CORONOR Investigators. Prognosis of patients with stable coronary artery disease (from the CORONOR study). Am J Cardiol. 2014;113(7):1142-5. doi:10.1016/j.amjcard.2013.12.019 · PMID 24507170G3
  33. Bauters C, Tricot O, Lemesle G, Meurice T, Hennebert O, Farnier M, et al. Reaching low-density lipoprotein cholesterol treatment targets in stable coronary artery disease: Determinants and prognostic impact. Arch Cardiovasc Dis. 2018;111(11):634-643. doi:10.1016/j.acvd.2017.07.007 · PMID 29198936G3
  34. Beavers CJ, Dobesh PP, Cushman M, DiDomenico RJ, Ijioma N, Joshi RV, et al. Multidisciplinary Approach to Antiplatelet Management in Coronary Syndromes: A Scientific Statement From the American Heart Association. Circulation. 2026;154(19):e687-e701. doi:10.1161/CIR.0000000000001478 · PMID 42866888C10G1
  35. Beltrame JF, Crea F, Kaski JC, Ogawa H, Ong P, Sechtem U, et al. International standardization of diagnostic criteria for vasospastic angina. Eur Heart J. 2017;38(33):2565-2568. doi:10.1093/eurheartj/ehv351 · PMID 26245334C7G1H1H3H5
  36. Beltrame JF. Management of vasospastic angina. Heart. 2022;109(1):70-77. doi:10.1136/heartjnl-2022-321268 · PMID 36371661C7H3
  37. Bergström G, Persson M, Adiels M, Björnson E, Bonander C, Ahlström H, et al. Prevalence of Subclinical Coronary Artery Atherosclerosis in the General Population. Circulation. 2021;144(12):916-929. doi:10.1161/CIRCULATIONAHA.121.055340 · PMID 34543072C6
  38. Berry C, Camici PG, Crea F, George M, Kaski JC, Ong P, et al. Clinical standards in angina and non-obstructive coronary arteries: A clinician and patient consensus statement. Int J Cardiol. 2025;429:133162. doi:10.1016/j.ijcard.2025.133162 · PMID 40088955G1H3
  39. Biscaglia S, Verardi FM, Tebaldi M, Guiducci V, Caglioni S, Campana R, et al. QFR-Based Virtual PCI or Conventional Angiography to Guide PCI: The AQVA Trial. JACC Cardiovasc Interv. 2023;16(7):783-794. doi:10.1016/j.jcin.2022.10.054 · PMID 36898939C9G2
  40. Björklund E, Nielsen SJ, Hansson EC, Karlsson M, Wallinder A, Martinsson A, et al. Secondary prevention medications after coronary artery bypass grafting and long-term survival: a population-based longitudinal study from the SWEDEHEART registry. Eur Heart J. 2020;41(17):1653-1661. doi:10.1093/eurheartj/ehz714 · PMID 31638654G3
  41. Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356(15):1503-16. doi:10.1056/NEJMoa070829 · PMID 17387127G2
  42. Boerhout CKM, de Waard GA, Lee JM, Mejia-Renteria H, Lee SH, Jung JH, et al. Prognostic value of structural and functional coronary microvascular dysfunction in patients with non-obstructive coronary artery disease; from the multicentre international ILIAS registry. EuroIntervention. 2022;18(9):719-728. doi:10.4244/EIJ-D-22-00043 · PMID 35694826H3
  43. Boerhout CKM, Namba HF, Liu T, Beijk MAM, Damman P, Meuwissen M, et al. Coronary function testing vs angiography alone to guide treatment of angina with non-obstructive coronary arteries: the ILIAS ANOCA trial. Eur Heart J. 2025;46(42):4396-4406. doi:10.1093/eurheartj/ehaf580 · PMID 40796241G2H3
  44. Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372(19):1791-800. doi:10.1056/NEJMoa1500857 · PMID 25773268C10G2I1
  45. Borrás X, Garcia-Moll X, Gómez-Doblas JJ, Zapata A, Artigas R, AVANCE study researchers. Stable angina in Spain and its impact on quality of life. The AVANCE registry. Rev Esp Cardiol (Engl Ed). 2012;65(8):734-41. doi:10.1016/j.rec.2012.03.010 · PMID 22739550G3
  46. Bradley CP, McKinley G, Orchard V, Tiller C, Stanley B, Ang D, et al. Endotype-informed therapy and effects on illness perception and psychological health in patients with chest pain and no obstructive coronary artery disease. Eur Heart J Qual Care Clin Outcomes. 2026;12(6):998-1008. doi:10.1093/ehjqcco/qcag081 · PMID 42241125G2G5
  47. Bradley CP, McKinley G, Orchard V, Tiller C, Stanley B, Ang D, et al. Endotyping-informed therapy for patients with chest pain and no obstructive coronary artery disease: a randomized trial. Nat Med. 2026;32(1):332-341. doi:10.1038/s41591-025-04044-4 · PMID 41214345G2G5
  48. Brandts J, Barkas F, De Bacquer D, Jennings C, De Backer GG, Kotseva K, et al. International patterns in lipid management and implications for patients with coronary heart disease: results from the INTERASPIRE study. Eur J Prev Cardiol. 2025. doi:10.1093/eurjpc/zwaf388 · PMID 40796307C8
  49. Braunwald E, Domanski MJ, Fowler SE, Geller NL, Gersh BJ, Hsia J, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med. 2004;351(20):2058-68. doi:10.1056/NEJMoa042739 · PMID 15531767C8G2
  50. Byrne RA, Joner M, Kastrati A. Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Grüntzig Lecture ESC 2014. Eur Heart J. 2015;36(47):3320-31. doi:10.1093/eurheartj/ehv511 · PMID 26417060C7
  51. Byrne RA, Fremes S, Capodanno D, Czerny M, Doenst T, Emberson JR, et al. 2022 Joint ESC/EACTS review of the 2018 guideline recommendations on the revascularization of left main coronary artery disease in patients at low surgical risk and anatomy suitable for PCI or CABG. Eur Heart J. 2023;44(41):4310-4320. doi:10.1093/eurheartj/ehad476 · PMID 37632756C9
  52. Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720-3826. doi:10.1093/eurheartj/ehad191 · PMID 37622654B4C7C10D1D4G1H4H5I1
  53. Bäck M, Wilhelm M, Marcin T, Machado FVC, Sandberg A, Buccheri S, et al. 2026 ESC Guidelines on cardiac rehabilitation. Eur Heart J. 2026;47(39):5631-5729. doi:10.1093/eurheartj/ehag099 · PMID 42661418B4C8D4G1
  54. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996;348(9038):1329-39. doi:10.1016/s0140-6736(96)09457-3 · PMID 8918275C10G2I1
  55. Carrabba N, Guaricci AI, Amico MA, Liga R, Podlesnikar T, Cvijić M, et al. Real-world implementation of ESC guidelines in chronic coronary syndromes: Insights from the EURECA registry with a focus on Italian practice. Int J Cardiol. 2026;465:134784. doi:10.1016/j.ijcard.2026.134784 · PMID 42744020G3
  56. Carrington JG, Nogami K, Kanaji Y, Lewis BR, Moustafa AO, Gulati R, et al. Classification and Outcomes of Coronary Microvascular Disease in Myocardial Infarction and Angina With Nonobstructive Coronary Arteries. Circ Cardiovasc Interv. 2026. doi:10.1161/CIRCINTERVENTIONS.126.016552 · PMID 42877957H3
  57. Castellano JM, Pocock SJ, Bhatt DL, Quesada AJ, Owen R, Fernandez-Ortiz A, et al. Polypill Strategy in Secondary Cardiovascular Prevention. N Engl J Med. 2022;387(11):967-977. doi:10.1056/NEJMoa2208275 · PMID 36018037C8
  58. Cequier Á, Bueno H, Macaya C, Bertomeu V, González-Juanatey JR, Íñiguez A, et al. Trends in cardiovascular care in the National Health System in Spain. Data from the RECALCAR project 2011-2020. Rev Esp Cardiol (Engl Ed). 2023;76(7):519-530. doi:10.1016/j.rec.2022.09.017 · PMID 36493955C2
  59. Chahine RA, Feldman RL, Giles TD, Nicod P, Raizner AE, Weiss RJ, et al. Randomized placebo-controlled trial of amlodipine in vasospastic angina. Amlodipine Study 160 Group. J Am Coll Cardiol. 1993;21(6):1365-70. doi:10.1016/0735-1097(93)90310-w · PMID 8166777I1
  60. Chaitman BR, Pepine CJ, Parker JO, Skopal J, Chumakova G, Kuch J, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA. 2004;291(3):309-16. doi:10.1001/jama.291.3.309 · PMID 14734593C4G2I1
  61. Chaitman BR, Skettino SL, Parker JO, Hanley P, Meluzin J, Kuch J, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol. 2004;43(8):1375-82. doi:10.1016/j.jacc.2003.11.045 · PMID 15093870C4
  62. Chang HJ, Lin FY, Gebow D, An HY, Andreini D, Bathina R, et al. Selective Referral Using CCTA Versus Direct Referral for Individuals Referred to Invasive Coronary Angiography for Suspected CAD: A Randomized, Controlled, Open-Label Trial. JACC Cardiovasc Imaging. 2019;12(7 Pt 2):1303-1312. doi:10.1016/j.jcmg.2018.09.018 · PMID 30553687G2
  63. Chi KY, Karthikeyan A, Chang Y, Lee PL, Mangalesh S, Hu JR, et al. Direct oral anticoagulant monotherapy vs combination therapy with antiplatelets in chronic coronary syndrome patients with prior percutaneous coronary intervention requiring anticoagulation: A meta-analysis. Am Heart J. 2026;300:107492. doi:10.1016/j.ahj.2026.107492 · PMID 42150734C10
  64. Chiang CY, Choi KC, Ho KM, Yu SF. Effectiveness of nurse-led patient-centered care behavioral risk modification on secondary prevention of coronary heart disease: A systematic review. Int J Nurs Stud. 2018;84:28-39. doi:10.1016/j.ijnurstu.2018.04.012 · PMID 29730084C8
  65. Chiew K, Foley MJ, Chotai S, Naderi Z, Rajkumar CA, Ahmed-Jushuf F, et al. Focal and Diffuse Coronary Artery Disease Patterns and Placebo-Controlled Angina Relief With Percutaneous Coronary Intervention: ORBITA-2. J Am Coll Cardiol. 2026;88(1):42-58. doi:10.1016/j.jacc.2026.02.5126 · PMID 42017887C9
  66. Cho MS, Kang DY, Ahn JM, Yun SC, Oh YS, Lee CH, et al. Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery Disease. N Engl J Med. 2024;391(22):2075-2086. doi:10.1056/NEJMoa2407362 · PMID 39225258C10G2
  67. Choi KH, Park YH, Lee JY, Jeong JO, Kim CJ, Yun KH, et al. Efficacy and safety of clopidogrel versus aspirin monotherapy in patients at high risk of subsequent cardiovascular event after percutaneous coronary intervention (SMART-CHOICE 3): a randomised, open-label, multicentre trial. Lancet. 2025;405(10486):1252-1263. doi:10.1016/S0140-6736(25)00449-0 · PMID 40174599C10G2G5I1
  68. Choi KH, Kang D, Kim W, Doh JH, Kim J, Park YH, et al. Discontinuation of Beta-Blocker Therapy after Myocardial Infarction. N Engl J Med. 2026;394(13):1302-1312. doi:10.1056/NEJMoa2601005 · PMID 41910427C4C7G2G5I1
  69. Cohn JN, Ziesche S, Smith R, Anand I, Dunkman WB, Loeb H, et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group. Circulation. 1997;96(3):856-63. doi:10.1161/01.cir.96.3.856 · PMID 9264493I1
  70. Collet C, Sonck J, Vandeloo B, Mizukami T, Roosens B, Lochy S, et al. Measurement of Hyperemic Pullback Pressure Gradients to Characterize Patterns of Coronary Atherosclerosis. J Am Coll Cardiol. 2019;74(14):1772-1784. doi:10.1016/j.jacc.2019.07.072 · PMID 31582137H1
  71. Collet C, Mizukami T, Bouisset F, Pontone G, Zivelonghi C, Jones DA, et al. Coronary CT Angiography versus Intravascular Ultrasound Guidance for PCI. N Engl J Med. 2026. doi:10.1056/NEJMoa2610771 · PMID 42969897C9G2G5
  72. Collison D, Didagelos M, Aetesam-Ur-Rahman M, Copt S, McDade R, McCartney P, et al. Post-stenting fractional flow reserve vs coronary angiography for optimization of percutaneous coronary intervention (TARGET-FFR). Eur Heart J. 2021;42(45):4656-4668. doi:10.1093/eurheartj/ehab449 · PMID 34279606C9G2
  73. Conn VS, Ruppar TM. Medication adherence outcomes of 771 intervention trials: Systematic review and meta-analysis. Prev Med. 2017;99:269-276. doi:10.1016/j.ypmed.2017.03.008 · PMID 28315760C8
  74. Connolly SJ, Eikelboom JW, Bosch J, Dagenais G, Dyal L, Lanas F, et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391(10117):205-218. doi:10.1016/S0140-6736(17)32458-3 · PMID 29132879I1
  75. Cordero A, Galve E, Bertomeu-Martínez V, Bueno H, Fácila L, Alegría E, et al. Trends in Risk Factors and Treatments in Patients With Stable Ischemic Heart Disease Seen at Cardiology Clinics Between 2006 and 2014. Rev Esp Cardiol (Engl Ed). 2016;69(4):401-7. doi:10.1016/j.rec.2015.08.011 · PMID 26631917G3
  76. Cordero A, Rodriguez Padial L, Batalla A, López Barreiro L, Torres Calvo F, Castellano JM, et al. Optimal pharmacological treatment and adherence to medication in secondary prevention of cardiovascular events in Spain: Results from the CAPS study. Cardiovasc Ther. 2017;35(2). doi:10.1111/1755-5922.12240 · PMID 27957818G3
  77. Correction to: 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2023;148(13):e148. doi:10.1161/CIR.0000000000001183 · PMID 37747957G1
  78. Correction to: 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2023;148(23):e186. doi:10.1161/CIR.0000000000001195 · PMID 38048397G1
  79. Correction to: 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC). Eur Heart J. 2024;45(7):518. doi:10.1093/eurheartj/ehad857 · PMID 38247449C8
  80. Correction to: 2024 ESC Guidelines for the management of chronic coronary syndromes: Developed by the task force for the management of chronic coronary syndromes of the European Society of Cardiology (ESC) Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2025;46(16):1565. doi:10.1093/eurheartj/ehaf079 · PMID 39982387C1G1
  81. Correction to: 2026 ESC Guidelines for the management of cardiovascular disease and chronic kidney disease, in collaboration with the European Renal Association (ERA): Developed by the task force on the management of cardiovascular disease and chronic kidney disease of the European Society of Cardiology (ESC). Eur Heart J. 2026. doi:10.1093/eurheartj/ehag884 · PMID 42927774C6
  82. Correction to: 2026 ESC Guidelines on cardiac rehabilitation: Developed by the task force on cardiac rehabilitation of the European Society of Cardiology (ESC)Endorsed by the European Society of Physical and Rehabilitation Medicine (ESPRM) and World Organization of Family Doctors (WONCA). Eur Heart J. 2026. doi:10.1093/eurheartj/ehag887 · PMID 42921976B4
  83. Costa F, van Klaveren D, James S, Heg D, Räber L, Feres F, et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet. 2017;389(10073):1025-1034. doi:10.1016/S0140-6736(17)30397-5 · PMID 28290994C7C10
  84. Costa F, Montalto C, Branca M, Hong SJ, Watanabe H, Franzone A, et al. Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: a meta-analysis of randomized trials. Eur Heart J. 2023;44(11):954-968. doi:10.1093/eurheartj/ehac706 · PMID 36477292C10
  85. Critchley J, Capewell S. Smoking cessation for the secondary prevention of coronary heart disease. Cochrane Database Syst Rev. 2004. doi:10.1002/14651858.CD003041.pub2 · PMID 14974003C8
  86. Crooijmans C, Jansen T, van de Hoef T, Paradies V, de Vos A, Yosofi B, et al. Design and rationale of the efficacy of endothelin receptor antagonism in treatment of coronary artery spasm: a randomized controlled trial (EDIT-CAS). Am Heart J. 2025;288:140-148. doi:10.1016/j.ahj.2025.04.022 · PMID 40274007G5
  87. Cury RC, Leipsic J, Abbara S, Achenbach S, Berman D, Bittencourt M, et al. CAD-RADS™ 2.0 - 2022 Coronary Artery Disease-Reporting and Data System: An Expert Consensus Document of the Society of Cardiovascular Computed Tomography (SCCT), the American College of Cardiology (ACC), the American College of Radiology (ACR), and the North America Society of Cardiovascular Imaging (NASCI). J Cardiovasc Comput Tomogr. 2022;16(6):536-557. doi:10.1016/j.jcct.2022.07.002 · PMID 35864070C5G1H5
  88. Curzen N, Nicholas Z, Stuart B, Wilding S, Hill K, Shambrook J, et al. Fractional flow reserve derived from computed tomography coronary angiography in the assessment and management of stable chest pain: the FORECAST randomized trial. Eur Heart J. 2021;42(37):3844-3852. doi:10.1093/eurheartj/ehab444 · PMID 34269376G2
  89. Cutlip DE, Mehran R, Sharma S, Doros G, Jefferson B, Stefanini G, et al. Sirolimus-Eluting Balloon vs Repeat Drug-Eluting Stent or Balloon Angioplasty for Coronary In-Stent Restenosis. J Am Coll Cardiol. 2026;88(1):62-72. doi:10.1016/j.jacc.2026.03.021 · PMID 41984017C9G2
  90. Daemen J, van der Eijk JA, Barbierato M, Byrne RA, Canova P, De Maria GL, et al. Angiography-Based Physiology to Guide Coronary Revascularization. N Engl J Med. 2026;395(1):20-31. doi:10.1056/NEJMoa2601841 · PMID 41910382C9G2
  91. Damluji AA, Nanna MG, Mason P, Lowenstern A, Orkaby AR, Washam JB, et al. Coronary Artery Revascularization in the Older Adult Population: A Scientific Statement From the American Heart Association. Circulation. 2025;152(25):e494-e525. doi:10.1161/CIR.0000000000001387 · PMID 41250995C6G1
  92. Damman K, Ter Maaten JM, Mayne KJ, Bolignano D, Brown EM, da Costa BR, et al. 2026 ESC Guidelines for the management of cardiovascular disease and chronic kidney disease, in collaboration with the European Renal Association (ERA). Eur Heart J. 2026. doi:10.1093/eurheartj/ehag098 · PMID 42661426C6G1I1
  93. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357(9266):1385-90. doi:10.1016/s0140-6736(00)04560-8 · PMID 11356434I1
  94. Davies A, Fox K, Galassi AR, Banai S, Ylä-Herttuala S, Lüscher TF. Management of refractory angina: an update. Eur Heart J. 2021;42(3):269-283. doi:10.1093/eurheartj/ehaa820 · PMID 33367764C9
  95. Davies JE, Sen S, Dehbi HM, Al-Lamee R, Petraco R, Nijjer SS, et al. Use of the Instantaneous Wave-free Ratio or Fractional Flow Reserve in PCI. N Engl J Med. 2017;376(19):1824-1834. doi:10.1056/NEJMoa1700445 · PMID 28317458G2
  96. Davies RF, Habibi H, Klinke WP, Dessain P, Nadeau C, Phaneuf DC, et al. Effect of amlodipine, atenolol and their combination on myocardial ischemia during treadmill exercise and ambulatory monitoring. Canadian Amlodipine/Atenolol in Silent Ischemia Study (CASIS) Investigators. J Am Coll Cardiol. 1995;25(3):619-25. doi:10.1016/0735-1097(94)00436-t · PMID 7860905I1
  97. De Bruyne B, Pijls NH, Kalesan B, Barbato E, Tonino PA, Piroth Z, et al. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med. 2012;367(11):991-1001. doi:10.1056/NEJMoa1205361 · PMID 22924638G2
  98. De Carlo M, Malanima MA, Baglietto L, Bazan L, Berti S, Calabrò P, et al. Standard clinical and stress electrocardiogram variables to exclude left main and left main-equivalent disease: the MASTER study. Eur Heart J. 2026. doi:10.1093/eurheartj/ehag464 · PMID 42489631C5
  99. De Luca L, Temporelli PL, Riccio C, Gonzini L, Marinacci L, Tartaglione SN, et al. Clinical outcomes, pharmacological treatment, and quality of life of patients with stable coronary artery diseases managed by cardiologists: 1-year results of the START study. Eur Heart J Qual Care Clin Outcomes. 2019;5(4):334-342. doi:10.1093/ehjqcco/qcz002 · PMID 30649303G3
  100. de Winter RW, Hoek R, Walsh SJ, Hanratty CG, Sprengers RW, Twisk JWR, et al. PCI of Native Coronary Artery vs Saphenous Vein Graft After Prior Bypass Surgery: A Multicenter, Randomized Trial. J Am Coll Cardiol. 2026;87(3):269-282. doi:10.1016/j.jacc.2025.09.1577 · PMID 41159978C9G2
  101. Del Buono MG, Montone RA, Camilli M, Carbone S, Narula J, Lavie CJ, et al. Coronary Microvascular Dysfunction Across the Spectrum of Cardiovascular Diseases: JACC State-of-the-Art Review. J Am Coll Cardiol. 2021;78(13):1352-1371. doi:10.1016/j.jacc.2021.07.042 · PMID 34556322H1
  102. DeMots H, Glasser SP. Intermittent transdermal nitroglycerin therapy in the treatment of chronic stable angina. J Am Coll Cardiol. 1989;13(4):786-95. doi:10.1016/0735-1097(89)90216-7 · PMID 2494240I1
  103. Desch S, Pugachova S, de Waha S, Thevathasan T, Freyer L, Stark K, et al. All-Cause Mortality Up to 20 Years After PCI or CABG for Left Main Disease. J Am Coll Cardiol. 2026. doi:10.1016/j.jacc.2026.08.006 · PMID 42671371C9
  104. Diletti R, Daemen J, Faurie B, Barbierato M, Tchétché D, Hovasse T, et al. Intravascular Ultrasound-Guided or Angiography-Guided Complex High-Risk PCI. N Engl J Med. 2026;394(22):2200-2211. doi:10.1056/NEJMoa2601521 · PMID 41911016C9G2
  105. DISCHARGE Trial Group, Maurovich-Horvat P, Bosserdt M, Kofoed KF, Rieckmann N, Benedek T, et al. CT or Invasive Coronary Angiography in Stable Chest Pain. N Engl J Med. 2022;386(17):1591-1602. doi:10.1056/NEJMoa2200963 · PMID 35240010G2
  106. Douglas PS, Hoffmann U, Patel MR, Mark DB, Al-Khalidi HR, Cavanaugh B, et al. Outcomes of anatomical versus functional testing for coronary artery disease. N Engl J Med. 2015;372(14):1291-300. doi:10.1056/NEJMoa1415516 · PMID 25773919G2
  107. Douglas PS, Nanna MG, Kelsey MD, Yow E, Mark DB, Patel MR, et al. Comparison of an Initial Risk-Based Testing Strategy vs Usual Testing in Stable Symptomatic Patients With Suspected Coronary Artery Disease: The PRECISE Randomized Clinical Trial. JAMA Cardiol. 2023;8(10):904-914. doi:10.1001/jamacardio.2023.2595 · PMID 37610731G2
  108. Ebrahimi F, Ebrahimi R, Beer M, Schönenberger CM, Ewald H, Briel M, et al. Colchicine for the secondary prevention of cardiovascular events. Cochrane Database Syst Rev. 2025;11(11):CD014808. doi:10.1002/14651858.CD014808.pub2 · PMID 41224205C8G5I1
  109. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353(9169):2001-7. doi:10.1016/S0140-6736(99)04440-2 · PMID 10376614I1
  110. Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II--DAVIT II). Am J Cardiol. 1990;66(10):779-85. doi:10.1016/0002-9149(90)90351-z · PMID 2220572I1
  111. Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 2017;377(14):1319-1330. doi:10.1056/NEJMoa1709118 · PMID 28844192C10G2I1
  112. Eikelboom JW, Xu L, Shoamanesh A, Dong Q, Hirano T, Saver JL, et al. Bleeding With Asundexian Versus Placebo in Patients With Noncardioembolic Ischemic Stroke or High-Risk TIA: OCEANIC-STROKE Randomized Trial. Circulation. 2026. doi:10.1161/CIRCULATIONAHA.126.081836 · PMID 42866879G5
  113. Einstein AJ, Williams MC, Weir-McCall JR, Shaw LJ, Karthikeyan G, Better N, et al. Worldwide Radiation Dose in Coronary Artery Disease Diagnostic Imaging. JAMA. 2026;335(13):1148-1158. doi:10.1001/jama.2026.0703 · PMID 41739468C5
  114. Elgendy IY, Mahmoud AN, Elgendy AY, Mojadidi MK, Elbadawi A, Eshtehardi P, et al. Drug-Eluting Balloons Versus Everolimus-Eluting Stents for In-Stent Restenosis: A Meta-Analysis of Randomized Trials. Cardiovasc Revasc Med. 2019;20(7):612-618. doi:10.1016/j.carrev.2018.08.010 · PMID 30126824C9
  115. Erdamar H, Sen N, Tavil Y, Yazici HU, Turfan M, Poyraz F, et al. The effect of nebivolol treatment on oxidative stress and antioxidant status in patients with cardiac syndrome-X. Coron Artery Dis. 2009;20(3):238-4. doi:10.1097/mca.0b013e32830936bb · PMID 19396947I1
  116. Escaned J, Berry C, De Bruyne B, Shabbir A, Collet C, Lee JM, et al. Applied coronary physiology for planning and guidance of percutaneous coronary interventions. A clinical consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the European Society of Cardiology. EuroIntervention. 2023;19(6):464-481. doi:10.4244/EIJ-D-23-00194 · PMID 37171503C9G1
  117. Escobar C, Gómez Lara J, Escaned J, Carol Ruiz A, Gutiérrez Ibañes E, Fernández Friera L, et al. Diagnosis and treatment of patients with ANOCA. Consensus document of the SEC-Clinical Cardiology Association/SEC-Interventional Cardiology Association/SEC-Ischemic Heart Disease and Acute Cardiac Care Association/ SEC-Cardiovascular Imaging Association. REC Interv Cardiol. 2024;6(2):106-116. doi:10.24875/RECICE.M23000420 · PMID 40416348G1H3
  118. Farkouh ME, Domanski M, Sleeper LA, Siami FS, Dangas G, Mack M, et al. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med. 2012;367(25):2375-84. doi:10.1056/NEJMoa1211585 · PMID 23121323C9G2
  119. Farkouh ME, Domanski M, Dangas GD, Godoy LC, Mack MJ, Siami FS, et al. Long-Term Survival Following Multivessel Revascularization in Patients With Diabetes: The FREEDOM Follow-On Study. J Am Coll Cardiol. 2019;73(6):629-638. doi:10.1016/j.jacc.2018.11.001 · PMID 30428398C9G2
  120. Fearon WF, Balsam LB, Farouque HM, Caffarelli AD, Robbins RC, Fitzgerald PJ, et al. Novel index for invasively assessing the coronary microcirculation. Circulation. 2003;107(25):3129-32. doi:10.1161/01.CIR.0000080700.98607.D1 · PMID 12821539H5
  121. Fearon WF, Zimmermann FM, De Bruyne B, Piroth Z, van Straten AHM, Szekely L, et al. Fractional Flow Reserve-Guided PCI as Compared with Coronary Bypass Surgery. N Engl J Med. 2022;386(2):128-137. doi:10.1056/NEJMoa2112299 · PMID 34735046C9G2
  122. Fearon WF, Zimmermann FM, Ding VY, Takahashi K, Piroth Z, van Straten AHM, et al. Outcomes after fractional flow reserve-guided percutaneous coronary intervention versus coronary artery bypass grafting (FAME 3): 5-year follow-up of a multicentre, open-label, randomised trial. Lancet. 2025;405(10488):1481-1490. doi:10.1016/S0140-6736(25)00505-7 · PMID 40174598C9G2
  123. Fearon WF, Jeremias A, Witberg G, Al-Lamee R, Cohen DJ, Kaki A, et al. Angiography-Derived Fractional Flow Reserve to Guide PCI. N Engl J Med. 2026;395(1):9-19. doi:10.1056/NEJMoa2600949 · PMID 41910384C9G2
  124. Fernández-Friera L, Peñalvo JL, Fernández-Ortiz A, Ibañez B, López-Melgar B, Laclaustra M, et al. Prevalence, Vascular Distribution, and Multiterritorial Extent of Subclinical Atherosclerosis in a Middle-Aged Cohort: The PESA (Progression of Early Subclinical Atherosclerosis) Study. Circulation. 2015;131(24):2104-13. doi:10.1161/CIRCULATIONAHA.114.014310 · PMID 25882487C6
  125. Fernández-Olmo R, Cordero A, Oterino A, Blanco-Echevarría A, Vivas D, Escobar C, et al. Planning of lipid-lowering treatment in atherosclerotic vascular disease. Consensus SEC/SEA/SEEN/SEMFYC/SEMERGEN/SEMG/SEN/SEACV/S.E.N. Clin Investig Arterioscler. 2025;37(4):500799. doi:10.1016/j.arteri.2025.500799 · PMID 40222857G1
  126. Ferrari R, Ford I, Fox K, Challeton JP, Correges A, Tendera M, et al. Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomised, double-blind, placebo-controlled trial. Lancet. 2020;396(10254):830-838. doi:10.1016/S0140-6736(20)31790-6 · PMID 32877651C4C7G2I1
  127. Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2012;126(25):e354-471. doi:10.1161/CIR.0b013e318277d6a0 · PMID 23166211G1
  128. Fihn SD, Blankenship JC, Alexander KP, Bittl JA, Byrne JG, Fletcher BJ, et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2014;130(19):1749-67. doi:10.1161/CIR.0000000000000095 · PMID 25070666G1
  129. Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26(3):215-25. doi:10.1093/eurheartj/ehi115 · PMID 15642700I1
  130. Foley L, Larkin J, Lombard-Vance R, Murphy AW, Hynes L, Galvin E, et al. Prevalence and predictors of medication non-adherence among people living with multimorbidity: a systematic review and meta-analysis. BMJ Open. 2021;11(9):e044987. doi:10.1136/bmjopen-2020-044987 · PMID 34475141C8
  131. Foley MJ, Rajkumar CA, Ahmed-Jushuf F, Simader FA, Chotai S, Pathimagaraj RH, et al. Coronary sinus reducer for the treatment of refractory angina (ORBITA-COSMIC): a randomised, placebo-controlled trial. Lancet. 2024;403(10436):1543-1553. doi:10.1016/S0140-6736(24)00256-3 · PMID 38604209C9G2G5
  132. Foley MJ, Rajkumar CA, Ahmed-Jushuf F, Simader F, Chotai S, Seligman H, et al. Fractional Flow Reserve and Instantaneous Wave-Free Ratio as Predictors of the Placebo-Controlled Response to Percutaneous Coronary Intervention in Stable Coronary Artery Disease. Circulation. 2025;151(3):202-214. doi:10.1161/CIRCULATIONAHA.124.072281 · PMID 39462291C9
  133. Foraker R, Sperling L, Bratzke L, Budoff M, Leppert M, Razavi AC, et al. Opportunistic Detection of Coronary Artery Calcium on Noncardiac Chest Computed Tomography: An Emerging Tool for Cardiovascular Disease Prevention: A Scientific Statement From the American Heart Association. Circulation. 2025;152(19):e391-e401. doi:10.1161/CIR.0000000000001382 · PMID 41099128C5
  134. Ford TJ, Stanley B, Good R, Rocchiccioli P, McEntegart M, Watkins S, et al. Stratified Medical Therapy Using Invasive Coronary Function Testing in Angina: The CorMicA Trial. J Am Coll Cardiol. 2018;72(23 Pt A):2841-2855. doi:10.1016/j.jacc.2018.09.006 · PMID 30266608G2H3
  135. Ford TJ, Stanley B, Sidik N, Good R, Rocchiccioli P, McEntegart M, et al. 1-Year Outcomes of Angina Management Guided by Invasive Coronary Function Testing (CorMicA). JACC Cardiovasc Interv. 2020;13(1):33-45. doi:10.1016/j.jcin.2019.11.001 · PMID 31709984G2H3
  136. Fox K, Garcia MA, Ardissino D, Buszman P, Camici PG, Crea F, et al. Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J. 2006;27(11):1341-81. doi:10.1093/eurheartj/ehl001 · PMID 16735367G1
  137. Fox K, Ford I, Steg PG, Tendera M, Ferrari R, BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9641):807-16. doi:10.1016/S0140-6736(08)61170-8 · PMID 18757088G2I1
  138. Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R, et al. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. Eur Heart J. 2009;30(19):2337-45. doi:10.1093/eurheartj/ehp358 · PMID 19720635I1
  139. Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R, et al. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med. 2014;371(12):1091-9. doi:10.1056/NEJMoa1406430 · PMID 25176136C4C7G2I1
  140. Fox KM, Mulcahy D, Findlay I, Ford I, Dargie HJ. The Total Ischaemic Burden European Trial (TIBET). Effects of atenolol, nifedipine SR and their combination on the exercise test and the total ischaemic burden in 608 patients with stable angina. The TIBET Study Group. Eur Heart J. 1996;17(1):96-103. doi:10.1093/oxfordjournals.eurheartj.a014699 · PMID 8682138I1
  141. Fox KM, EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362(9386):782-8. doi:10.1016/s0140-6736(03)14286-9 · PMID 13678872G2
  142. Fuller RH, Perel P, Navarro-Ruan T, Nieuwlaat R, Haynes RB, Huffman MD. Improving medication adherence in patients with cardiovascular disease: a systematic review. Heart. 2018;104(15):1238-1243. doi:10.1136/heartjnl-2017-312571 · PMID 29572248C8
  143. Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation. 1995;92(5):1326-31. doi:10.1161/01.cir.92.5.1326 · PMID 7648682I1
  144. Gabaldón-Pérez A, Bonanad C, García-Blas S, Gavara J, Ríos-Navarro C, Pérez-Solé N, et al. Stress cardiac magnetic resonance for mortality prediction and decision-making: registry of 2496 elderly patients with chronic coronary syndrome. Rev Esp Cardiol (Engl Ed). 2022;75(3):223-231. doi:10.1016/j.rec.2021.08.004 · PMID 34548244G3
  145. Galassi AR, Werner GS, Boukhris M, Azzalini L, Mashayekhi K, Carlino M, et al. Percutaneous recanalisation of chronic total occlusions: 2019 consensus document from the EuroCTO Club. EuroIntervention. 2019;15(2):198-208. doi:10.4244/EIJ-D-18-00826 · PMID 30636678H5
  146. Galassi AR, Vadalà G, Werner GS, Cosyns B, Sianos G, Hill J, et al. Evaluation and management of patients with coronary chronic total occlusions considered for revascularisation. A clinical consensus statement of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC, the European Association of Cardiovascular Imaging (EACVI) of the ESC, and the ESC Working Group on Cardiovascular Surgery. EuroIntervention. 2024;20(3):e174-e184. doi:10.4244/EIJ-D-23-00749 · PMID 38343372C9G1
  147. Galli M, Vinciguerra M, Laudani C, Occhipinti G, D'Amario D, Iaconelli A, et al. Oral Anticoagulation With or Without Antiplatelet Therapy in Chronic Coronary Syndrome: A Meta-Analysis of Randomized Trials. JACC Cardiovasc Interv. 2026;19(10):1294-1306. doi:10.1016/j.jcin.2026.03.020 · PMID 42191321C10
  148. Galve E, Cordero A, Cequier A, Ruiz E, González-Juanatey JR. Degree of Lipid Control in Patients With Coronary Heart Disease and Measures Adopted by Physicians. REPAR Study. Rev Esp Cardiol (Engl Ed). 2016;69(10):931-938. doi:10.1016/j.rec.2016.02.012 · PMID 27178117G3
  149. Gandhi S, Chen S, Hong L, Sun K, Gong E, Li C, et al. Effect of Mobile Health Interventions on the Secondary Prevention of Cardiovascular Disease: Systematic Review and Meta-analysis. Can J Cardiol. 2017;33(2):219-231. doi:10.1016/j.cjca.2016.08.017 · PMID 27956043C8
  150. Ganyukov VI, Kochergin NA, Shilov AA, Tarasov RS, Skupien J, Kozyrin KA, et al. Randomized Clinical Trial of Surgical Versus Percutaneous Versus Hybrid Multivessel Coronary Revascularization: 3 Years' Follow-Up. JACC Cardiovasc Interv. 2021;14(10):1163-1165. doi:10.1016/j.jcin.2021.02.037 · PMID 34016423C9
  151. Gao X, Kan J, Chen Y, Chen X, Wang Y, Zeng H, et al. IVUS or Angiography Guidance for Percutaneous Coronary Intervention in Complex Coronary Bifurcation Lesions: The DKCRUSH VIII Randomized Clinical Trial. J Am Coll Cardiol. 2026;87(16):2080-2095. doi:10.1016/j.jacc.2026.01.081 · PMID 41914946C9G2
  152. Garcia RA, Spertus JA, Benton MC, Jones PG, Mark DB, Newman JD, et al. Association of Medication Adherence With Health Outcomes in the ISCHEMIA Trial. J Am Coll Cardiol. 2022;80(8):755-765. doi:10.1016/j.jacc.2022.05.045 · PMID 35981820C8
  153. Gasimova NZ, Paltsev AA, Zayachkovskiy NA, Nezdorovina VG, Nezdorovin OV, Bortsova MA, et al. Prospective evaluation of spinal cord stimulation in refractory angina: insights from a single-center cohort. Front Cardiovasc Med. 2025;12:1681623. doi:10.3389/fcvm.2025.1681623 · PMID 41437995G5
  154. Giacoppo D, Alfonso F, Xu B, Claessen BEPM, Adriaenssens T, Jensen C, et al. Drug-Coated Balloon Angioplasty Versus Drug-Eluting Stent Implantation in Patients With Coronary Stent Restenosis. J Am Coll Cardiol. 2020;75(21):2664-2678. doi:10.1016/j.jacc.2020.04.006 · PMID 32466881C9
  155. Giacoppo D, Alvarez-Covarrubias HA, Koch T, Cassese S, Xhepa E, Kessler T, et al. Coronary artery restenosis treatment with plain balloon, drug-coated balloon, or drug-eluting stent: 10-year outcomes of the ISAR-DESIRE 3 trial. Eur Heart J. 2023;44(15):1343-1357. doi:10.1093/eurheartj/ehad026 · PMID 36807512C9G2
  156. Gibson CM, Steg PG, Bahit MC, Al-Lamee R, Mehta SR, Mehran R, et al. Milvexian with Antiplatelet Therapy after Acute Coronary Syndrome Event. N Engl J Med. 2026;395(16):1575-1584. doi:10.1056/NEJMoa2608717 · PMID 42670965G5
  157. Gimelli A, Neglia D, Cvijić M, Pontone G, Miglioranza MH, Guaricci AI, et al. Radiation burden of contemporary diagnostic pathways for chronic coronary syndromes: an ancillary analysis of the international EURECA Imaging Registry. Eur Heart J Cardiovasc Imaging. 2026. doi:10.1093/ehjci/jeag274 · PMID 42802617G3
  158. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. Lancet. 1994;343(8906):1115-22. PMID 7910229I1
  159. Glasser SP. Effect of extended-release isosorbide mononitrate one hour after dosing in patients with stable angina pectoris. IMDUR Study Group. Am J Cardiol. 1997;80(12):1546-50. doi:10.1016/s0002-9149(97)00802-3 · PMID 9416933I1
  160. Godoy LC, Farkouh ME, Austin PC, Shah BR, Qiu F, Jackevicius CA, et al. Association of Beta-Blocker Therapy With Cardiovascular Outcomes in Patients With Stable Ischemic Heart Disease. J Am Coll Cardiol. 2023;81(24):2299-2311. doi:10.1016/j.jacc.2023.04.021 · PMID 37316110C4
  161. Gomez-Barrado JJ, Gomez-Turegano P, Ortiz-Cortes C, Vega-Fernandez J, Gomez-Turegano M, Garciperez de Vargas FJ, et al. Low-Density Lipoprotein Cholesterol Targets in Patients With Coronary Heart Disease in Extremadura (Spain): LYNX Registry. Cardiol Res. 2020;11(5):311-318. doi:10.14740/cr1079 · PMID 32849966G3
  162. Gragnano F, Cao D, Pirondini L, Franzone A, Kim HS, von Scheidt M, et al. P2Y(12) Inhibitor or Aspirin Monotherapy for Secondary Prevention of Coronary Events. J Am Coll Cardiol. 2023;82(2):89-105. doi:10.1016/j.jacc.2023.04.051 · PMID 37407118C10
  163. Greenwood JP, Ripley DP, Berry C, McCann GP, Plein S, Bucciarelli-Ducci C, et al. Effect of Care Guided by Cardiovascular Magnetic Resonance, Myocardial Perfusion Scintigraphy, or NICE Guidelines on Subsequent Unnecessary Angiography Rates: The CE-MARC 2 Randomized Clinical Trial. JAMA. 2016;316(10):1051-60. doi:10.1001/jama.2016.12680 · PMID 27570866G2
  164. Grigorian-Shamagian L, Oteo JF, Gutiérrez-Barrios A, Abdul-Jawad Altisent O, Amat-Santos I, Cisnal AF, et al. Endothelial dysfunction in patients with angina and non-obstructed coronary arteries is associated with an increased risk of mayor cardiovascular events. Results of the Spanish ENDOCOR registry. Int J Cardiol. 2023;370:18-25. doi:10.1016/j.ijcard.2022.10.169 · PMID 36328111G3
  165. Gulati M, Levy PD, Mukherjee D, Amsterdam E, Bhatt DL, Birtcher KK, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021;144(22):e368-e454. doi:10.1161/CIR.0000000000001029 · PMID 34709879D4G1H4
  166. Gungor G, Perk H, Soyupek S, Baykal B, Demir M, Sezer MT. Nebivolol protects erectile functions compared to Metoprolol in hypertensive men with atherogenic, venogenic, psychogenic erectile dysfunction: A prospective, randomized, cross-over, clinical trial. Eur J Intern Med. 2022;103:69-75. doi:10.1016/j.ejim.2022.06.013 · PMID 35752527C7
  167. Gámez JM, Ripoll T, Barrios V, Anguita M, Pedreira M, Madariaga I, et al. The clinical profile of women with stable ischaemic heart disease in Spain. More effort is needed in secondary prevention. SIRENA study. Rev Clin Esp (Barc). 2016;216(1):1-7. doi:10.1016/j.rce.2015.09.012 · PMID 26548859G3
  168. Gómez-Barrado JJ, Gómez-Turégano P, Gómez-Turégano M. Impact of the COVID-19 pandemic on clinical profile and LDL cholesterol control in patients with chronic coronary síndrome. Clin Investig Arterioscler. 2026. doi:10.1016/j.arteri.2026.500965 · PMID 42754418G3
  169. Götberg M, Christiansen EH, Gudmundsdottir IJ, Sandhall L, Danielewicz M, Jakobsen L, et al. Instantaneous Wave-free Ratio versus Fractional Flow Reserve to Guide PCI. N Engl J Med. 2017;376(19):1813-1823. doi:10.1056/NEJMoa1616540 · PMID 28317438G2
  170. Halvorsen S, Mehilli J, Cassese S, Hall TS, Abdelhamid M, Barbato E, et al. 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. Eur Heart J. 2022;43(39):3826-3924. doi:10.1093/eurheartj/ehac270 · PMID 36017553C6C10G1I1
  171. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351(9118):1755-62. doi:10.1016/s0140-6736(98)04311-6 · PMID 9635947I1
  172. Head SJ, Milojevic M, Daemen J, Ahn JM, Boersma E, Christiansen EH, et al. Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data. Lancet. 2018;391(10124):939-948. doi:10.1016/S0140-6736(18)30423-9 · PMID 29478841C7C9
  173. Heart Outcomes Prevention Evaluation Study Investigators, Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342(3):145-53. doi:10.1056/NEJM200001203420301 · PMID 10639539C8G2
  174. Hecht HS, Cronin P, Blaha MJ, Budoff MJ, Kazerooni EA, Narula J, et al. 2016 SCCT/STR guidelines for coronary artery calcium scoring of noncontrast noncardiac chest CT scans: A report of the Society of Cardiovascular Computed Tomography and Society of Thoracic Radiology. J Cardiovasc Comput Tomogr. 2017;11(1):74-84. doi:10.1016/j.jcct.2016.11.003 · PMID 27916431C5
  175. Hochman JS, Anthopolos R, Reynolds HR, Bangalore S, Xu Y, O'Brien SM, et al. Survival After Invasive or Conservative Management of Stable Coronary Disease. Circulation. 2023;147(1):8-19. doi:10.1161/CIRCULATIONAHA.122.062714 · PMID 36335918C9G2G5
  176. Hochman JS, Anthopolos R, Reynolds HR, Bangalore S, Xu Y, O'Brien SM, et al. Long-Term Survival After Initial Invasive or Conservative Management of Stable Coronary Disease in ISCHEMIA-EXTEND. JAMA. 2026. doi:10.1001/jama.2026.20375 · PMID 42998244C9G2G5
  177. Hokimoto S, Kaikita K, Yasuda S, Tsujita K, Ishihara M, Matoba T, et al. JCS/CVIT/JCC 2023 Guideline Focused Update on Diagnosis and Treatment of Vasospastic Angina (Coronary Spastic Angina) and Coronary Microvascular Dysfunction. Circ J. 2023;87(6):879-936. doi:10.1253/circj.CJ-22-0779 · PMID 36908169G1H3
  178. Holck EN, Holm NR, Hildick-Smith D, Lindsay MM, Spence MS, Erglis A, et al. Percutaneous coronary intervention versus coronary artery bypass grafting for unprotected left main stenosis: 10-year final results from the randomised, open-label, non-inferiority NOBLE trial. Lancet. 2026;407(10536):1374-1382. doi:10.1016/S0140-6736(26)00205-9 · PMID 41936368C9G2
  179. Holm NR, Mäkikallio T, Lindsay MM, Spence MS, Erglis A, Menown IBA, et al. Percutaneous coronary angioplasty versus coronary artery bypass grafting in the treatment of unprotected left main stenosis: updated 5-year outcomes from the randomised, non-inferiority NOBLE trial. Lancet. 2020;395(10219):191-199. doi:10.1016/S0140-6736(19)32972-1 · PMID 31879028C9G2
  180. Holm NR, Andreasen LD, Neghabat O, Laanmets P, Kumsars I, Bennett J, et al. OCT or Angiography Guidance for PCI in Complex Bifurcation Lesions. N Engl J Med. 2023;389(16):1477-1487. doi:10.1056/NEJMoa2307770 · PMID 37634149C9G2
  181. Hoppe S, Rusicka T, Klimowicz J, Harat M. Long-Term, Time-Dependent Effects of Spinal Cord Stimulation for Refractory Angina Pectoris: A Prospective, Longitudinal Study. Neuromodulation. 2026;29(1):122-128. doi:10.1016/j.neurom.2025.10.068 · PMID 41342825G5
  182. Hu X, Zhang J, Yang S, Jiang J, Peng X, Lu D, et al. Angiography-derived fractional flow reserve versus intravascular ultrasound to guide percutaneous coronary intervention in patients with coronary artery disease (FLAVOUR II): a multicentre, randomised, non-inferiority trial. Lancet. 2025;405(10488):1491-1504. doi:10.1016/S0140-6736(25)00504-5 · PMID 40174597C9G2
  183. Ibanez B, Latini R, Rossello X, Dominguez-Rodriguez A, Fernández-Vazquez F, Pelizzoni V, et al. Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction. N Engl J Med. 2025;393(19):1889-1900. doi:10.1056/NEJMoa2504735 · PMID 40888702C4C7G5
  184. IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet. 2002;359(9314):1269-75. doi:10.1016/S0140-6736(02)08265-X · PMID 11965271C4G2I1
  185. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet. 1995;345(8951):669-85. doi:10.1016/s0140-6736(95)90865-x · PMID 7661937I1
  186. Jansen TPJ, Konst RE, de Vos A, Paradies V, Teerenstra S, van den Oord SCH, et al. Efficacy of Diltiazem to Improve Coronary Vasomotor Dysfunction in ANOCA: The EDIT-CMD Randomized Clinical Trial. JACC Cardiovasc Imaging. 2022;15(8):1473-1484. doi:10.1016/j.jcmg.2022.03.012 · PMID 35466050G2H3I1
  187. Jespersen L, Hvelplund A, Abildstrøm SZ, Pedersen F, Galatius S, Madsen JK, et al. Stable angina pectoris with no obstructive coronary artery disease is associated with increased risks of major adverse cardiovascular events. Eur Heart J. 2012;33(6):734-44. doi:10.1093/eurheartj/ehr331 · PMID 21911339G3H3
  188. Jimenez-Heffernan A, Aguade-Bruix S, Casans-Tormo I. Nuclear cardiology practice in Spain. J Nucl Cardiol. 2017;24(6):2133-2140. doi:10.1007/s12350-017-0912-1 · PMID 28493201C2
  189. Johnson SM, Mauritson DR, Willerson JT, Hillis LD. A controlled trial of verapamil for Prinzmetal's variant angina. N Engl J Med. 1981;304(15):862-6. doi:10.1056/NEJM198104093041502 · PMID 6782480I1
  190. Johnson TW, Gonzalo N, de la Torre Hernandez JM, Amabile N, O'Kane P, Alasnag M, et al. Intracoronary imaging for left main percutaneous coronary intervention: a clinical consensus statement of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC and the European Bifurcation Club (EBC). Eur Heart J. 2026;47(37):5247-5265. doi:10.1093/eurheartj/ehag353 · PMID 42135060C9G1
  191. Jolly SS, d'Entremont MA, Lee SF, Mian R, Tyrwhitt J, Kedev S, et al. Colchicine in Acute Myocardial Infarction. N Engl J Med. 2025;392(7):633-642. doi:10.1056/NEJMoa2405922 · PMID 39555823C8G5I1
  192. Jones WS, Mulder H, Wruck LM, Pencina MJ, Kripalani S, Muñoz D, et al. Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease. N Engl J Med. 2021;384(21):1981-1990. doi:10.1056/NEJMoa2102137 · PMID 33999548I1
  193. Kang J, Park KW, Lee H, Hwang D, Yang HM, Rha SW, et al. Aspirin Versus Clopidogrel for Long-Term Maintenance Monotherapy After Percutaneous Coronary Intervention: The HOST-EXAM Extended Study. Circulation. 2023;147(2):108-117. doi:10.1161/CIRCULATIONAHA.122.062770 · PMID 36342475C10G2I1
  194. Kang J, Park S, Yang HM, Shin ES, Rha SW, Bae JW, et al. Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention: 10-year follow-up of the HOST-EXAM trial. Lancet. 2026;407(10537):1439-1447. doi:10.1016/S0140-6736(26)00422-8 · PMID 41921522C10G2I1
  195. Kang Y, Zhao Z, Yang Z, Zeng L, Qu N, Zhang Q, et al. Beta-Blockers and Outcome in Patients with Suspected Coronary Artery Disease Evaluated Noninvasively. Am J Med. 2025;138(9):1257-1263.e1. doi:10.1016/j.amjmed.2025.04.019 · PMID 40345513C4
  196. Kantor PF, Lucien A, Kozak R, Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res. 2000;86(5):580-8. doi:10.1161/01.res.86.5.580 · PMID 10720420I1
  197. Kayaalti F, Kalay N, Basar E, Mavili E, Duran M, Ozdogru I, et al. Effects of nebivolol therapy on endothelial functions in cardiac syndrome X. Heart Vessels. 2010;25(2):92-6. doi:10.1007/s00380-009-1170-1 · PMID 20339969I1
  198. Kerneis M, Cosentino F, Ferrari R, Georges JL, Kosmachova E, Laroche C, et al. Impact of chronic coronary syndromes on cardiovascular hospitalization and mortality: the ESC-EORP CICD-LT registry. Eur J Prev Cardiol. 2022;29(15):1945-1954. doi:10.1093/eurjpc/zwac089 · PMID 35653582G3
  199. Khan S, Sajjad U, Fawaz S, Butt H, Simpson R, Ibrahim A, et al. Randomized, Placebo-Controlled Trial of Chronic Total Occlusion Percutaneous Coronary Intervention in Stable Angina: The ORBITA-CTO Trial. J Am Coll Cardiol. 2026;88(1):4-18. doi:10.1016/j.jacc.2026.03.027 · PMID 41999379C9G2
  200. Knuuti J, Ballo H, Juarez-Orozco LE, Saraste A, Kolh P, Rutjes AWS, et al. The performance of non-invasive tests to rule-in and rule-out significant coronary artery stenosis in patients with stable angina: a meta-analysis focused on post-test disease probability. Eur Heart J. 2018;39(35):3322-3330. doi:10.1093/eurheartj/ehy267 · PMID 29850808C5
  201. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407-477. doi:10.1093/eurheartj/ehz425 · PMID 31504439C7G1H5
  202. Koeckerling D, Reddy RK, Howard JP, Bansal R, Bernstein H, Lehmann L, et al. Long-Term Mortality After PCI or CABG for Left Main Stem Disease: Updated Meta-Analysis of Randomized Trials Using Reconstructed Individual-Participant Survival Data. J Am Coll Cardiol. 2026;87(16):2180-2183. doi:10.1016/j.jacc.2026.01.079 · PMID 41879579C9
  203. Komajda M, Cosentino F, Ferrari R, Kerneis M, Kosmachova E, Laroche C, et al. Profile and treatment of chronic coronary syndromes in European Society of Cardiology member countries: The ESC EORP CICD-LT registry. Eur J Prev Cardiol. 2021;28(4):432-445. doi:10.1177/2047487320912491 · PMID 33966083G3
  204. Koo BK, Kang J, Park KW, Rhee TM, Yang HM, Won KB, et al. Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial. Lancet. 2021;397(10293):2487-2496. doi:10.1016/S0140-6736(21)01063-1 · PMID 34010616C10G2I1
  205. Kosiborod M, Arnold SV, Spertus JA, McGuire DK, Li Y, Yue P, et al. Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina). J Am Coll Cardiol. 2013;61(20):2038-45. doi:10.1016/j.jacc.2013.02.011 · PMID 23500237C4G2I1
  206. Kosmidou I, Leon MB, Zhang Y, Serruys PW, von Birgelen C, Smits PC, et al. Long-Term Outcomes in Women and Men Following Percutaneous Coronary Intervention. J Am Coll Cardiol. 2020;75(14):1631-1640. doi:10.1016/j.jacc.2020.01.056 · PMID 32273029C6
  207. Kristensen AMD, Rossello X, Atar D, Yndigegn T, Kimura T, Latini R, et al. Beta-Blockers after Myocardial Infarction with Normal Ejection Fraction. N Engl J Med. 2026;394(6):540-550. doi:10.1056/NEJMoa2512686 · PMID 41211954C4G5
  208. Kumbhani DJ, Gibson CM, Kinlay S, Peterson ED, Pollak AW, Tamis-Holland JE, et al. Antiplatelet Therapy in the Management of Atherosclerotic Cardiovascular Disease: 2026 ACC Scientific Statement: A Report of the American College of Cardiology. J Am Coll Cardiol. 2026;88(11):1284-1313. doi:10.1016/j.jacc.2026.05.037 · PMID 42377293C10G1
  209. Kunadian V, Chieffo A, Camici PG, Berry C, Escaned J, Maas AHEM, et al. An EAPCI Expert Consensus Document on Ischaemia with Non-Obstructive Coronary Arteries in Collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcirculation Endorsed by Coronary Vasomotor Disorders International Study Group. Eur Heart J. 2020;41(37):3504-3520. doi:10.1093/eurheartj/ehaa503 · PMID 32626906C7G1H1H3I1
  210. Køber L, Adamo M, Ruwald AC, Tomasoni D, Anderson LJ, Andersson C, et al. 2026 ESC Guidelines for the management of heart failure. Eur Heart J. 2026;47(38):5346-5457. doi:10.1093/eurheartj/ehag100 · PMID 42661420C6C7C8G1I1
  211. Lamy A, Eikelboom J, Sheth T, Connolly S, Bosch J, Fox KAA, et al. Rivaroxaban, Aspirin, or Both to Prevent Early Coronary Bypass Graft Occlusion: The COMPASS-CABG Study. J Am Coll Cardiol. 2019;73(2):121-130. doi:10.1016/j.jacc.2018.10.048 · PMID 30654882C10G2
  212. Lanza GA, Sestito A, Sgueglia GA, Infusino F, Manolfi M, Crea F, et al. Current clinical features, diagnostic assessment and prognostic determinants of patients with variant angina. Int J Cardiol. 2007;118(1):41-7. doi:10.1016/j.ijcard.2006.06.016 · PMID 16889844H3
  213. Lapa ME, Swabe GM, Rollman BL, Muldoon MF, Thurston RC, Magnani JW. Assessment of Depression and Adherence to Guideline-Directed Medical Therapies Following Percutaneous Coronary Intervention. JAMA Netw Open. 2022;5(12):e2246317. doi:10.1001/jamanetworkopen.2022.46317 · PMID 36508214C8
  214. Laudani C, Occhipinti G, Costa F, D'Amario D, Palmerini T, Sciarretta S, et al. Aspirin vs clopidogrel in chronic coronary syndromes: a meta-analysis of ethnic differences. Eur Heart J. 2026. doi:10.1093/eurheartj/ehag351 · PMID 42154959C10I1
  215. Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM, Bischoff JM, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(3):e18-e114. doi:10.1161/CIR.0000000000001038 · PMID 34882435C9G1
  216. Lee JM, Choi KH, Song YB, Lee JY, Lee SJ, Lee SY, et al. Intravascular Imaging-Guided or Angiography-Guided Complex PCI. N Engl J Med. 2023;388(18):1668-1679. doi:10.1056/NEJMoa2216607 · PMID 36876735C9G2
  217. Lee JM, Kim O, Song YB, Lee JY, Lee SJ, Lee SY, et al. Intravascular Imaging- vs Angiography-Guided Complex PCI: 5-Year Outcomes From a Randomized Trial. J Am Coll Cardiol. 2026;87(16):2099-2113. doi:10.1016/j.jacc.2026.01.035 · PMID 41778943C9G2
  218. Lee SH, Shin D, Lee JM, van de Hoef TP, Hong D, Choi KH, et al. Clinical Relevance of Ischemia with Nonobstructive Coronary Arteries According to Coronary Microvascular Dysfunction. J Am Heart Assoc. 2022;11(9):e025171. doi:10.1161/JAHA.121.025171 · PMID 35475358H3
  219. Lee SJ, Lee YJ, Lee K, Cho DK, Cho YH, Ahn SG, et al. Clopidogrel or Dual Antiplatelet Therapy in High-Ischemic-Risk Patients. N Engl J Med. 2026. doi:10.1056/NEJMoa2608533 · PMID 42670964C10G2G5
  220. Lee SJ, Yu HT, Lee YJ, Lee SH, Heo JH, Ahn SG, et al. Therapy for Atrial Fibrillation in Patients with Drug-Eluting Stents. N Engl J Med. 2026;394(7):658-668. doi:10.1056/NEJMoa2512091 · PMID 41211917C10G2
  221. Lee SW, Lee PH, Ahn JM, Park DW, Yun SC, Han S, et al. Randomized Trial Evaluating Percutaneous Coronary Intervention for the Treatment of Chronic Total Occlusion. Circulation. 2019;139(14):1674-1683. doi:10.1161/CIRCULATIONAHA.118.031313 · PMID 30813758C9G2
  222. Lemesle G, Lamblin N, Schurtz G, Labreuche J, Duhamel A, Verdier B, et al. Comparison of Incidence and Prognostic Impact of Ischemic, Major Bleeding and Heart Failure Events in Patients With Chronic Coronary Syndrome: Insights From the CORONOR Registry. Circulation. 2024;149(22):1708-1716. doi:10.1161/CIRCULATIONAHA.123.067938 · PMID 38660793G3
  223. Lemesle G, Didier R, Steg PG, Simon T, Montalescot G, Danchin N, et al. Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation. N Engl J Med. 2025;393(16):1578-1588. doi:10.1056/NEJMoa2507532 · PMID 40888725C10G2G5I1
  224. Lenell J, Flores Tomasino G, Han D, Wolny R, Park C, Grodecki K, et al. Improved plaque composition from intensive medical treatment in women with angina and non-obstructive coronary disease. Cardiovasc Res. 2026. doi:10.1093/cvr/cvag174 · PMID 42841236G5
  225. Li Y, Li J, Wang B, Jing Q, Zeng Y, Hou A, et al. Extended Clopidogrel Monotherapy vs DAPT in Patients With Acute Coronary Syndromes at High Ischemic and Bleeding Risk: The OPT-BIRISK Randomized Clinical Trial. JAMA Cardiol. 2024;9(6):523-531. doi:10.1001/jamacardio.2024.0534 · PMID 38630489C10G2
  226. Lie JT. Centenary of the first correct antemortem diagnosis of coronary thrombosis by Adam Hammer (1818--1878): English translation of the original report. Am J Cardiol. 1978;42(5):849-52. doi:10.1016/0002-9149(78)90106-6 · PMID 360811C7
  227. Lin S, Su X, Ma H, Dou K, Song L, Zhao H, et al. Real-Time Heart Team for Revascularization in Complex Coronary Artery Disease: The EHEART Randomized Trial. J Am Coll Cardiol. 2026;87(24):3467-3479. doi:10.1016/j.jacc.2026.01.010 · PMID 41778947C9G2
  228. Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563 · PMID 37952131C8G2
  229. Lindholt JS, Søgaard R, Rasmussen LM, Mejldal A, Lambrechtsen J, Steffensen FH, et al. Five-Year Outcomes of the Danish Cardiovascular Screening (DANCAVAS) Trial. N Engl J Med. 2022;387(15):1385-1394. doi:10.1056/NEJMoa2208681 · PMID 36027560C6G2
  230. Lip GYH, Kuzma L. Revisiting direct oral anticoagulant monotherapy vs combination therapy with antiplatelets in chronic coronary syndrome patients with prior percutaneous coronary intervention: Balancing thromboembolism, mortality and bleeding. Am Heart J. 2026;300:107509. doi:10.1016/j.ahj.2026.107509 · PMID 42264426C10
  231. Lo CK, Ip NH, Sin TH, Ho SY, Wong CK, Tam FC, et al. Randomized controlled trial of vericiguat in patients with coronary microvascular dysfunction causing stable chest pain (V-COM): study protocol for a randomized control trial. J Cardiovasc Magn Reson. 2026;28(1):102744. doi:10.1016/j.jocmr.2026.102744 · PMID 42128362G5
  232. Lopes RD, Heizer G, Aronson R, Vora AN, Massaro T, Mehran R, et al. Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. N Engl J Med. 2019;380(16):1509-1524. doi:10.1056/NEJMoa1817083 · PMID 30883055C10G2I1
  233. Lowenstern A, Wu J, Bradley SM, Fanaroff AC, Tcheng JE, Wang TY. Current landscape of hybrid revascularization: A report from the NCDR CathPCI Registry. Am Heart J. 2019;215:167-177. doi:10.1016/j.ahj.2019.06.014 · PMID 31349108C9
  234. Lubbers M, Dedic A, Coenen A, Galema T, Akkerhuis J, Bruning T, et al. Calcium imaging and selective computed tomography angiography in comparison to functional testing for suspected coronary artery disease: the multicentre, randomized CRESCENT trial. Eur Heart J. 2016;37(15):1232-43. doi:10.1093/eurheartj/ehv700 · PMID 26746631G2
  235. Lubsen J, Wagener G, Kirwan BA, de Brouwer S, Poole-Wilson PA, ACTION (A Coronary disease Trial Investigating Outcome with Nifedipine GITS) investigators. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial. J Hypertens. 2005;23(3):641-8. doi:10.1097/01.hjh.0000160223.94220.29 · PMID 15716708I1
  236. Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229-4361. doi:10.1093/eurheartj/ehac244 · PMID 36017568C6
  237. Mach F, Koskinas KC, Roeters van Lennep JE, Tokgözoğlu L, Badimon L, Baigent C, et al. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2025;46(42):4359-4378. doi:10.1093/eurheartj/ehaf190 · PMID 40878289C5C7C8G1
  238. Maddox TM, Stanislawski MA, Grunwald GK, Bradley SM, Ho PM, Tsai TT, et al. Nonobstructive coronary artery disease and risk of myocardial infarction. JAMA. 2014;312(17):1754-63. doi:10.1001/jama.2014.14681 · PMID 25369489G3
  239. Madhavan MV, Kirtane AJ, Redfors B, Généreux P, Ben-Yehuda O, Palmerini T, et al. Stent-Related Adverse Events >1 Year After Percutaneous Coronary Intervention. J Am Coll Cardiol. 2020;75(6):590-604. doi:10.1016/j.jacc.2019.11.058 · PMID 32057373C7
  240. Mahtani KR, Heneghan CJ, Glasziou PP, Perera R. Reminder packaging for improving adherence to self-administered long-term medications. Cochrane Database Syst Rev. 2011. doi:10.1002/14651858.CD005025.pub3 · PMID 21901694C8
  241. Marcos-Garces V, Gavara J, Monmeneu JV, Lopez-Lereu MP, Bosch MJ, Merlos P, et al. Vasodilator Stress CMR and All-Cause Mortality in Stable Ischemic Heart Disease: A Large Retrospective Registry. JACC Cardiovasc Imaging. 2020;13(8):1674-1686. doi:10.1016/j.jcmg.2020.02.027 · PMID 32682717G3
  242. Mark DB, Shaw L, Harrell FE Jr, Hlatky MA, Lee KL, Bengtson JR, et al. Prognostic value of a treadmill exercise score in outpatients with suspected coronary artery disease. N Engl J Med. 1991;325(12):849-53. doi:10.1056/NEJM199109193251204 · PMID 1875969C5
  243. Maron DJ, Hochman JS, Reynolds HR, Bangalore S, O'Brien SM, Boden WE, et al. Initial Invasive or Conservative Strategy for Stable Coronary Disease. N Engl J Med. 2020;382(15):1395-1407. doi:10.1056/NEJMoa1915922 · PMID 32227755C9G2
  244. Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043-4140. doi:10.1093/eurheartj/ehad192 · PMID 37622663C6C8G1
  245. Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371(23):2155-66. doi:10.1056/NEJMoa1409312 · PMID 25399658C10G2I1
  246. Mazzolai L, Teixido-Tura G, Lanzi S, Boc V, Bossone E, Brodmann M, et al. 2024 ESC Guidelines for the management of peripheral arterial and aortic diseases. Eur Heart J. 2024;45(36):3538-3700. doi:10.1093/eurheartj/ehae179 · PMID 39210722C6I1
  247. McClelland RL, Chung H, Detrano R, Post W, Kronmal RA. Distribution of coronary artery calcium by race, gender, and age: results from the Multi-Ethnic Study of Atherosclerosis (MESA). Circulation. 2006;113(1):30-7. doi:10.1161/CIRCULATIONAHA.105.580696 · PMID 16365194C5C7
  248. McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45(38):3912-4018. doi:10.1093/eurheartj/ehae178 · PMID 39210715C6G1I1
  249. McFalls EO, Ward HB, Moritz TE, Goldman S, Krupski WC, Littooy F, et al. Coronary-artery revascularization before elective major vascular surgery. N Engl J Med. 2004;351(27):2795-804. doi:10.1056/NEJMoa041905 · PMID 15625331C6G2
  250. McKavanagh P, Lusk L, Ball PA, Verghis RM, Agus AM, Trinick TR, et al. A comparison of cardiac computerized tomography and exercise stress electrocardiogram test for the investigation of stable chest pain: the clinical results of the CAPP randomized prospective trial. Eur Heart J Cardiovasc Imaging. 2015;16(4):441-8. doi:10.1093/ehjci/jeu284 · PMID 25473041G2
  251. Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366(1):9-19. doi:10.1056/NEJMoa1112277 · PMID 22077192I1
  252. Mehran R, Baber U, Sharma SK, Cohen DJ, Angiolillo DJ, Briguori C, et al. Ticagrelor with or without Aspirin in High-Risk Patients after PCI. N Engl J Med. 2019;381(21):2032-2042. doi:10.1056/NEJMoa1908419 · PMID 31556978C10G2I1
  253. Mendieta G, Pocock S, Mass V, Moreno A, Owen R, García-Lunar I, et al. Determinants of Progression and Regression of Subclinical Atherosclerosis Over 6 Years. J Am Coll Cardiol. 2023;82(22):2069-2083. doi:10.1016/j.jacc.2023.09.814 · PMID 37993199C7
  254. Mesnier J, Ducrocq G, Danchin N, Ferrari R, Ford I, Tardif JC, et al. International Observational Analysis of Evolution and Outcomes of Chronic Stable Angina: The Multinational CLARIFY Study. Circulation. 2021;144(7):512-523. doi:10.1161/CIRCULATIONAHA.121.054567 · PMID 34261331B4C9G3
  255. Migliaro S, Petrolini A, Mariani S, Tomai F. Impact of renal denervation on patients with coronary microvascular dysfunction: study rationale and design. J Cardiovasc Med (Hagerstown). 2024;25(5):379-385. doi:10.2459/JCM.0000000000001609 · PMID 38477865G5
  256. Mileva N, Nagumo S, Mizukami T, Sonck J, Berry C, Gallinoro E, et al. Prevalence of Coronary Microvascular Disease and Coronary Vasospasm in Patients With Nonobstructive Coronary Artery Disease: Systematic Review and Meta-Analysis. J Am Heart Assoc. 2022;11(7):e023207. doi:10.1161/JAHA.121.023207 · PMID 35301851H3
  257. Mills NL, Newby LK, Zaman S, Almahmeed WA, Bucciarelli-Ducci C, Colvin MM, et al. Fifth Universal Definition of Myocardial Infarction (2026). Eur Heart J. 2026;47(40):5911-5958. doi:10.1093/eurheartj/ehag101 · PMID 42661425G1H5
  258. Min JK, Dunning A, Lin FY, Achenbach S, Al-Mallah M, Budoff MJ, et al. Age- and sex-related differences in all-cause mortality risk based on coronary computed tomography angiography findings results from the International Multicenter CONFIRM (Coronary CT Angiography Evaluation for Clinical Outcomes: An International Multicenter Registry) of 23,854 patients without known coronary artery disease. J Am Coll Cardiol. 2011;58(8):849-60. doi:10.1016/j.jacc.2011.02.074 · PMID 21835321G3
  259. Miner S, Mejia-Renteria H, Leone AM, Velollari O, Sykes R, Biscaglia S, et al. Endotypes of angina with non-obstructive coronary arteries: a prospective multicentre study. Eur Heart J. 2026;47(5):594-604. doi:10.1093/eurheartj/ehaf839 · PMID 41214896H3
  260. Moayyedi P, Eikelboom JW, Bosch J, Connolly SJ, Dyal L, Shestakovska O, et al. Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. Gastroenterology. 2019;157(3):682-691.e2. doi:10.1053/j.gastro.2019.05.056 · PMID 31152740C10G2
  261. Morice MC, Serruys PW, Kappetein AP, Feldman TE, Ståhle E, Colombo A, et al. Five-year outcomes in patients with left main disease treated with either percutaneous coronary intervention or coronary artery bypass grafting in the synergy between percutaneous coronary intervention with taxus and cardiac surgery trial. Circulation. 2014;129(23):2388-94. doi:10.1161/CIRCULATIONAHA.113.006689 · PMID 24700706C9G2
  262. Morrow A, Young R, Abraham GR, Hoole S, Greenwood JP, Arnold JR, et al. Zibotentan in Microvascular Angina: A Randomized, Placebo-Controlled, Crossover Trial. Circulation. 2024;150(21):1671-1683. doi:10.1161/CIRCULATIONAHA.124.069901 · PMID 39217504G2G5H3
  263. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, Murphy SA, Budaj A, Varshavsky S, et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA. 2007;297(16):1775-83. doi:10.1001/jama.297.16.1775 · PMID 17456819I1
  264. Mortensen MB, Gaur S, Frimmer A, Bøtker HE, Sørensen HT, Kragholm KH, et al. Association of Age With the Diagnostic Value of Coronary Artery Calcium Score for Ruling Out Coronary Stenosis in Symptomatic Patients. JAMA Cardiol. 2022;7(1):36-44. doi:10.1001/jamacardio.2021.4406 · PMID 34705022C5
  265. Motivala AA, Parikh V, Roe M, Dai D, Abbott JD, Prasad A, et al. Predictors, Trends, and Outcomes (Among Older Patients ≥65 Years of Age) Associated With Beta-Blocker Use in Patients With Stable Angina Undergoing Elective Percutaneous Coronary Intervention: Insights From the NCDR Registry. JACC Cardiovasc Interv. 2016;9(16):1639-48. doi:10.1016/j.jcin.2016.05.048 · PMID 27539683C4
  266. Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med. 1988;319(7):385-92. doi:10.1056/NEJM198808183190701 · PMID 2899840I1
  267. Munkhaugen J, Kristensen AMD, Halvorsen S, Holmager T, Olsen MH, Bakken A, et al. Beta-Blockers after Myocardial Infarction in Patients without Heart Failure. N Engl J Med. 2025;393(19):1901-1911. doi:10.1056/NEJMoa2505985 · PMID 40888716C4C7G5
  268. Nakamura K, Henry TD, Traverse JH, Latter DA, Mokadam NA, Answini GA, et al. Angiogenic Gene Therapy for Refractory Angina: Results of the EXACT Phase 2 Trial. Circ Cardiovasc Interv. 2024;17(5):e014054. doi:10.1161/CIRCINTERVENTIONS.124.014054 · PMID 38696284G5
  269. Namba HF, de Jong EAM, Dimitriu-Leen AC, Meuwissen M, Heestermans TACM, den Haan MC, et al. Vericiguat for the Treatment of Coronary Vasospasm (ViVA): A Double-Blind Placebo-Controlled Randomized Crossover Trial. J Am Coll Cardiol. 2026. doi:10.1016/j.jacc.2026.08.037 · PMID 42670734G2G5
  270. Navarese EP, Lansky AJ, Kereiakes DJ, Kubica J, Gurbel PA, Gorog DA, et al. Cardiac mortality in patients randomised to elective coronary revascularisation plus medical therapy or medical therapy alone: a systematic review and meta-analysis. Eur Heart J. 2021;42(45):4638-4651. doi:10.1093/eurheartj/ehab246 · PMID 34002203C9
  271. Navarese EP, Landi A, Oliva A, Piccolo R, Aboyans V, Angiolillo D, et al. Within and beyond 12-month efficacy and safety of antithrombotic strategies in patients with established coronary artery disease: two companion network meta-analyses of the 2022 joint clinical consensus statement of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Association for Acute CardioVascular Care (ACVC), and European Association of Preventive Cardiology (EAPC). Eur Heart J Cardiovasc Pharmacother. 2023;9(3):271-290. doi:10.1093/ehjcvp/pvad016 · PMID 36869784C10
  272. Neglia D, Liga R, Gimelli A, Podlesnikar T, Cvijić M, Pontone G, et al. Use of cardiac imaging in chronic coronary syndromes: the EURECA Imaging registry. Eur Heart J. 2023;44(2):142-158. doi:10.1093/eurheartj/ehac640 · PMID 36452988G3
  273. Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019;40(2):87-165. doi:10.1093/eurheartj/ehy394 · PMID 30165437C9G1
  274. Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ, et al. Colchicine in Patients with Chronic Coronary Disease. N Engl J Med. 2020;383(19):1838-1847. doi:10.1056/NEJMoa2021372 · PMID 32865380C8G2I1
  275. Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA. 2004;292(18):2217-25. doi:10.1001/jama.292.18.2217 · PMID 15536108I1
  276. Ojha U, Mohsin M, Macierzanka K, Ahmed-Jushuf F, Rajkumar CA, Chotai S, et al. Safety, Efficacy, and Effectiveness of Coronary Sinus Reducer Implantation in Refractory Angina: A Meta-Analysis. JACC Cardiovasc Interv. 2025;18(15):1864-1877. doi:10.1016/j.jcin.2025.06.012 · PMID 40803761C9
  277. Ommen SR, Ho CY, Asif IM, Balaji S, Burke MA, Day SM, et al. 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149(23):e1239-e1311. doi:10.1161/CIR.0000000000001250 · PMID 38718139C6
  278. Ong P, Athanasiadis A, Borgulya G, Vokshi I, Bastiaenen R, Kubik S, et al. Clinical usefulness, angiographic characteristics, and safety evaluation of intracoronary acetylcholine provocation testing among 921 consecutive white patients with unobstructed coronary arteries. Circulation. 2014;129(17):1723-30. doi:10.1161/CIRCULATIONAHA.113.004096 · PMID 24573349H3
  279. Ong P, Camici PG, Beltrame JF, Crea F, Shimokawa H, Sechtem U, et al. International standardization of diagnostic criteria for microvascular angina. Int J Cardiol. 2018;250:16-20. doi:10.1016/j.ijcard.2017.08.068 · PMID 29031990G1H3
  280. Ong P, Camici PG, Beltrame J, Berry C, Crea F, Escaned J, et al. 2026 update on the COVADIS diagnostic criteria of international standardization for microvascular angina. Int J Cardiol. 2026;466:134993. doi:10.1016/j.ijcard.2026.134993 · PMID 42874788G1H1H3H5
  281. Opstal TSJ, Fiolet ATL, van Broekhoven A, Mosterd A, Eikelboom JW, Nidorf SM, et al. Colchicine in Patients With Chronic Coronary Disease in Relation to Prior Acute Coronary Syndrome. J Am Coll Cardiol. 2021;78(9):859-866. doi:10.1016/j.jacc.2021.06.037 · PMID 34446156I1
  282. Packer M, O'Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med. 1996;335(15):1107-14. doi:10.1056/NEJM199610103351504 · PMID 8813041I1
  283. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344(22):1651-8. doi:10.1056/NEJM200105313442201 · PMID 11386263I1
  284. Packer M, Carson P, Elkayam U, Konstam MA, Moe G, O'Connor C, et al. Effect of amlodipine on the survival of patients with severe chronic heart failure due to a nonischemic cardiomyopathy: results of the PRAISE-2 study (prospective randomized amlodipine survival evaluation 2). JACC Heart Fail. 2013;1(4):308-314. doi:10.1016/j.jchf.2013.04.004 · PMID 24621933I1
  285. Panza JA, Ellis AM, Al-Khalidi HR, Holly TA, Berman DS, Oh JK, et al. Myocardial Viability and Long-Term Outcomes in Ischemic Cardiomyopathy. N Engl J Med. 2019;381(8):739-748. doi:10.1056/NEJMoa1807365 · PMID 31433921C9H5
  286. Parada-Barcia JA, Rodríguez-Pérez Á, Eiros-Bachiller R, Chaparro-Muñoz M, Rodríguez-Palomares J, Fernández-Golfin C, et al. Current indications for cardiac magnetic resonance and cardiac computed tomography: a position statement from the Cardiovascular Imaging Association of the Spanish Society of Cardiology. Rev Esp Cardiol (Engl Ed). 2026. doi:10.1016/j.rec.2026.06.015 · PMID 42710805C2
  287. Park DW, Ahn JM, Park H, Yun SC, Kang DY, Lee PH, et al. Ten-Year Outcomes After Drug-Eluting Stents Versus Coronary Artery Bypass Grafting for Left Main Coronary Disease: Extended Follow-Up of the PRECOMBAT Trial. Circulation. 2020;141(18):1437-1446. doi:10.1161/CIRCULATIONAHA.120.046039 · PMID 32223567C9G2
  288. Park DW, Kang DY, Ahn JM, Yun SC, Yoon YH, Hur SH, et al. Routine Functional Testing or Standard Care in High-Risk Patients after PCI. N Engl J Med. 2022;387(10):905-915. doi:10.1056/NEJMoa2208335 · PMID 36036496B4B6C8D1G2
  289. Pedretti RFE, Hansen D, Ambrosetti M, Back M, Berger T, Ferreira MC, et al. How to optimize the adherence to a guideline-directed medical therapy in the secondary prevention of cardiovascular diseases: a clinical consensus statement from the European Association of Preventive Cardiology. Eur J Prev Cardiol. 2023;30(2):149-166. doi:10.1093/eurjpc/zwac204 · PMID 36098041C8
  290. Pepine CJ, Cohn PF, Deedwania PC, Gibson RS, Handberg E, Hill JA, et al. Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life. The Atenolol Silent Ischemia Study (ASIST). Circulation. 1994;90(2):762-8. doi:10.1161/01.cir.90.2.762 · PMID 8044945I1
  291. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290(21):2805-16. doi:10.1001/jama.290.21.2805 · PMID 14657064I1
  292. Pepine CJ, Handberg E, Cooper-DeHoff R, Cook-Wiens G, Diniz MA, Frayne S, et al. Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD (WARRIOR): a randomised controlled trial. Open Heart. 2026;13(1). doi:10.1136/openhrt-2026-004115 · PMID 41932694G2G5H3
  293. Perera D, Clayton T, O'Kane PD, Greenwood JP, Weerackody R, Ryan M, et al. Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction. N Engl J Med. 2022;387(15):1351-1360. doi:10.1056/NEJMoa2206606 · PMID 36027563C9G2
  294. Perera D, Ryan M, Morgan HP, Greenwood JP, Petrie MC, Dodd M, et al. Viability and Outcomes With Revascularization or Medical Therapy in Ischemic Ventricular Dysfunction: A Prespecified Secondary Analysis of the REVIVED-BCIS2 Trial. JAMA Cardiol. 2023;8(12):1154-1161. doi:10.1001/jamacardio.2023.3803 · PMID 37878295C9H5
  295. Perera D, Ryan M, Ezad SM, Khan SQ, Webb I, O'Kane PD, et al. Left Ventricular Unloading in High-Risk Percutaneous Coronary Intervention. N Engl J Med. 2026;394(18):1779-1789. doi:10.1056/NEJMoa2515704 · PMID 41910380C9G2
  296. Picano E, Pierard L, Peteiro J, Djordjevic-Dikic A, Sade LE, Cortigiani L, et al. The clinical use of stress echocardiography in chronic coronary syndromes and beyond coronary artery disease: a clinical consensus statement from the European Association of Cardiovascular Imaging of the ESC. Eur Heart J Cardiovasc Imaging. 2024;25(2):e65-e90. doi:10.1093/ehjci/jead250 · PMID 37798126G1
  297. Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini GB, Miller ME, et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation. 2000;102(13):1503-10. doi:10.1161/01.cir.102.13.1503 · PMID 11004140I1
  298. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362(9377):7-13. doi:10.1016/S0140-6736(03)13800-7 · PMID 12853193I1
  299. Poole-Wilson PA, Lubsen J, Kirwan BA, van Dalen FJ, Wagener G, Danchin N, et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet. 2004;364(9437):849-57. doi:10.1016/S0140-6736(04)16980-8 · PMID 15351192I1
  300. Praz F, Borger MA, Lanz J, Marin-Cuartas M, Abreu A, Adamo M, et al. 2025 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2025;46(44):4635-4736. doi:10.1093/eurheartj/ehaf194 · PMID 40878295C6G1
  301. Rajiah PS, Alkadhi H, Andreini D, Bullock-Palmer RP, Chinnaiyan KM, Chow BJW, et al. Interpretation and reporting of coronary computed tomographic angiography (2026 update): An expert consensus document of the Society of Cardiovascular Computed Tomography (SCCT). J Cardiovasc Comput Tomogr. 2026;20(5):459-482. doi:10.1016/j.jcct.2026.08.014 · PMID 42864251C5G1
  302. Rajkumar CA, Foley MJ, Ahmed-Jushuf F, Nowbar AN, Simader FA, Davies JR, et al. A Placebo-Controlled Trial of Percutaneous Coronary Intervention for Stable Angina. N Engl J Med. 2023;389(25):2319-2330. doi:10.1056/NEJMoa2310610 · PMID 38015442C7C9G2
  303. Ramaseshan R, Perera D, Reid A, Andiapen M, Ariti C, Kelham M, et al. REGENERATE-COBRA: A phase II randomized sham-controlled trial assessing the safety and efficacy of intracoronary administration of autologous bone marrow-derived cells in patients with refractory angina. Am Heart J. 2024;275:96-104. doi:10.1016/j.ahj.2024.06.001 · PMID 38862073G5
  304. Rasmussen LD, Schmidt SE, Knuuti J, Newby DE, Singh T, Nieman K, et al. Exercise electrocardiography for pre-test assessment of the likelihood of coronary artery disease. Heart. 2024;110(4):263-270. doi:10.1136/heartjnl-2023-322970 · PMID 37607813C5
  305. Rehnqvist N, Hjemdahl P, Billing E, Björkander I, Eriksson SV, Forslund L, et al. Effects of metoprolol vs verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm (APSIS). Eur Heart J. 1996;17(1):76-81. doi:10.1093/oxfordjournals.eurheartj.a014695 · PMID 8682134I1
  306. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017;377(12):1119-1131. doi:10.1056/NEJMoa1707914 · PMID 28845751G2
  307. Ridker PM, Everett BM, Pradhan A, MacFadyen JG, Solomon DH, Zaharris E, et al. Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. N Engl J Med. 2019;380(8):752-762. doi:10.1056/NEJMoa1809798 · PMID 30415610G2
  308. Roe MT, Armstrong PW, Fox KA, White HD, Prabhakaran D, Goodman SG, et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med. 2012;367(14):1297-309. doi:10.1056/NEJMoa1205512 · PMID 22920930I1
  309. Rossello X, Prescott EIB, Kristensen AMD, Latini R, Fuster V, Fagerland MW, et al. β blockers after myocardial infarction with mildly reduced ejection fraction: an individual patient data meta-analysis of randomised controlled trials. Lancet. 2025;406(10508):1128-1137. doi:10.1016/S0140-6736(25)01592-2 · PMID 40897190C4G5
  310. Rossello X, Barrabés JA, Piepoli M, Dominguez-Rodriguez A, Sánchez PL, Anguita M, et al. Effect of beta blockers in acute and chronic coronary syndromes without reduced ejection fraction: a landmark analysis from the REBOOT trial. Eur Heart J Cardiovasc Pharmacother. 2026;12(2):64-74. doi:10.1093/ehjcvp/pvag002 · PMID 41564893C4G5
  311. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-33. doi:10.1001/jama.288.3.321 · PMID 12117397C6
  312. Roubille F, Kharlamov JA, Lenz M, Madonna R, Delmas C, Schaubroeck H, et al. Inflammation in coronary syndromes in clinical practice: a clinical consensus statement of the Association for Acute Cardiovascular Care of the European Society of Cardiology, the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases, the European Society of Cardiology Council on Basic Cardiovascular Science, and the European Society of Cardiology Council for Cardiology Practice. Eur Heart J Acute Cardiovasc Care. 2026;15(10):788-803. doi:10.1093/ehjacc/zuag086 · PMID 42536391G5
  313. Ruel M, Sandner S, Ponnambalam M, Brown C, Gaudino M, Sun L, et al. Secondary Prevention After Coronary Artery Bypass Graft Surgery: 2026 Update: A Scientific Statement From the American Heart Association. Circulation. 2026;153(25):e1408-e1426. doi:10.1161/CIR.0000000000001434 · PMID 42125794G1
  314. Rumiz E, Fuertes G, Pérez A, Llopis G, Cerdán L, Vadillo P, et al. Prognostic stratification of patients with nonobstructive coronary artery disease managed according to invasive coronary function testing. Rev Esp Cardiol (Engl Ed). 2026;79(7):593-602. doi:10.1016/j.rec.2025.11.012 · PMID 41308737G3
  315. Rumiz E, Rivero F, Pérez A, Nau G, Romero M, Solana S, et al. ESP-INOCA: Rationale and design of a national multicentre registry for prognostic stratification in patients with suspected myocardial ischaemia and non-obstructive coronary arteries. Int J Cardiol. 2026;442:133845. doi:10.1016/j.ijcard.2025.133845 · PMID 40886802G3
  316. Ruzyllo W, Tendera M, Ford I, Fox KM. Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial. Drugs. 2007;67(3):393-405. doi:10.2165/00003495-200767030-00005 · PMID 17335297I1
  317. Råmunddal T, Holck EN, Karim S, Eftekhari A, Escaned J, Ioanes D, et al. International randomized trial on the effect of revascularization or optimal medical therapy of chronic total coronary occlusions with myocardial ischemia - ISCHEMIA-CTO trial - rationale and design. Am Heart J. 2023;257:41-50. doi:10.1016/j.ahj.2022.11.016 · PMID 36423733G5
  318. Sabatine MS, Bergmark BA, Murphy SA, O'Gara PT, Smith PK, Serruys PW, et al. Percutaneous coronary intervention with drug-eluting stents versus coronary artery bypass grafting in left main coronary artery disease: an individual patient data meta-analysis. Lancet. 2021;398(10318):2247-2257. doi:10.1016/S0140-6736(21)02334-5 · PMID 34793745C9
  319. Salinas P, Sánchez-Rubio J, Jurado-Román A, Moreiras JM. Spanish cardiac catheterization and interventional cardiology registry. 35(th) official report of the Interventional Cardiology Association of the Spanish Society of Cardiology (1990-2025). Rev Esp Cardiol (Engl Ed). 2026. doi:10.1016/j.rec.2026.06.020 · PMID 42951129H2
  320. Sandner S, Redfors B, Angiolillo DJ, Audisio K, Fremes SE, Janssen PWA, et al. Association of Dual Antiplatelet Therapy With Ticagrelor With Vein Graft Failure After Coronary Artery Bypass Graft Surgery: A Systematic Review and Meta-analysis. JAMA. 2022;328(6):554-562. doi:10.1001/jama.2022.11966 · PMID 35943473C10
  321. Sandner S, Gaudino M, Agewall S, Bonalumi G, Bonaros N, Czerny M, et al. Antithrombotic therapy after coronary artery bypass graft surgery: a Clinical Consensus Statement of the ESC Working Group on Cardiovascular Surgery, the ESC Working Group on Cardiovascular Pharmacotherapy, and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2026;47(20):2419-2436. doi:10.1093/eurheartj/ehaf423 · PMID 40884067B4C10G1
  322. Sandoval Y, Leipsic J, Collet C, Ali ZA, Azzalini L, Barbato E, et al. Coronary computed tomography angiography to guide percutaneous coronary intervention: Expert opinion from a SCAI/SCCT roundtable. J Cardiovasc Comput Tomogr. 2025;19(3):277-290. doi:10.1016/j.jcct.2025.04.015 · PMID 40360362G1
  323. Sato K, Takahashi J, Odaka Y, Suda A, Sueda S, Teragawa H, et al. Clinical characteristics and long-term prognosis of contemporary patients with vasospastic angina: Ethnic differences detected in an international comparative study. Int J Cardiol. 2019;291:13-18. doi:10.1016/j.ijcard.2019.02.038 · PMID 30819587C7H3
  324. Savonitto S, Ardissiono D, Egstrup K, Rasmussen K, Bae EA, Omland T, et al. Combination therapy with metoprolol and nifedipine versus monotherapy in patients with stable angina pectoris. Results of the International Multicenter Angina Exercise (IMAGE) Study. J Am Coll Cardiol. 1996;27(2):311-6. doi:10.1016/0735-1097(95)00489-0 · PMID 8557899I1
  325. Schäfer A, Alasnag M, Giacoppo D, Collet C, Rudolph TK, Roguin A, et al. High-risk percutaneous coronary intervention in patients with reduced left ventricular ejection fraction deemed not suitable for surgical revascularisation. A clinical consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) in collaboration with the ESC Working Group on Cardiovascular Surgery. EuroIntervention. 2025;21(1):22-34. doi:10.4244/EIJ-D-23-01100 · PMID 39773827C9G1
  326. Scirica BM, Morrow DA, Hod H, Murphy SA, Belardinelli L, Hedgepeth CM, et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation. 2007;116(15):1647-52. doi:10.1161/CIRCULATIONAHA.107.724880 · PMID 17804441I1
  327. SCOT-HEART investigators. CT coronary angiography in patients with suspected angina due to coronary heart disease (SCOT-HEART): an open-label, parallel-group, multicentre trial. Lancet. 2015;385(9985):2383-91. doi:10.1016/S0140-6736(15)60291-4 · PMID 25788230G2
  328. SCOT-HEART Investigators, Newby DE, Adamson PD, Berry C, Boon NA, Dweck MR, et al. Coronary CT Angiography and 5-Year Risk of Myocardial Infarction. N Engl J Med. 2018;379(10):924-933. doi:10.1056/NEJMoa1805971 · PMID 30145934G2
  329. SEC Working Group for the 2018 ESC/EACTS Guidelines for Myocardial Revascularization, Expert Reviewers for the 2018 ESC/EACTS Guidelines for Myocardial Revascularization, SEC Guidelines Committee. Comments on the 2018 ESC/EACTS Guidelines for Myocardial Revascularization. Rev Esp Cardiol (Engl Ed). 2019;72(1):16-20. doi:10.1016/j.rec.2018.11.010 · PMID 30580785C9G1
  330. SEC Working Group for the 2019 ESC guidelines on chronic coronary syndromes, Expert Reviewers for the 2019 ESC guidelines on chronic coronary syndromes, SEC Guidelines Committe, SEC Working Group for the 2019 ESC guidelines on chronic coronary syndromes, SEC Guidelines Committee. Comments on the 2019 ESC guidelines on chronic coronary syndromes. Rev Esp Cardiol (Engl Ed). 2020;73(6):439-444. doi:10.1016/j.rec.2019.12.023 · PMID 32376227G1
  331. SEC Working Group for the 2024 ESC guidelines for the management of chronic coronary syndromes and SEC Guidelines Committee. Comments on the ESC 2024 guidelines for the management of chronic coronary syndromes. Rev Esp Cardiol (Engl Ed). 2025;78(3):170-175. doi:10.1016/j.rec.2024.10.007 · PMID 39488327G1
  332. Sharma M, Dong Q, Hirano T, Kasner SE, Saver JL, Masjuan J, et al. Asundexian for Secondary Stroke Prevention. N Engl J Med. 2026;394(15):1467-1479. doi:10.1056/NEJMoa2513880 · PMID 41985132G5
  333. Shaw LJ, Mieres JH, Hendel RH, Boden WE, Gulati M, Veledar E, et al. Comparative effectiveness of exercise electrocardiography with or without myocardial perfusion single photon emission computed tomography in women with suspected coronary artery disease: results from the What Is the Optimal Method for Ischemia Evaluation in Women (WOMEN) trial. Circulation. 2011;124(11):1239-49. doi:10.1161/CIRCULATIONAHA.111.029660 · PMID 21844080C5G2
  334. Shimokawa H, Suda A, Takahashi J, Berry C, Camici PG, Crea F, et al. Clinical characteristics and prognosis of patients with microvascular angina: an international and prospective cohort study by the Coronary Vasomotor Disorders International Study (COVADIS) Group. Eur Heart J. 2021;42(44):4592-4600. doi:10.1093/eurheartj/ehab282 · PMID 34038937G3
  335. Sianos G, Morel MA, Kappetein AP, Morice MC, Colombo A, Dawkins K, et al. The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention. 2005;1(2):219-27. PMID 19758907H5
  336. Silvain J, Lattuca B, Beygui F, Rangé G, Motovska Z, Dillinger JG, et al. Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial. Lancet. 2020;396(10264):1737-1744. doi:10.1016/S0140-6736(20)32236-4 · PMID 33202219C10G2I1
  337. Silvain J, Cayla G, Ferrari E, Range G, Puymirat E, Delarche N, et al. Beta-Blocker Interruption or Continuation after Myocardial Infarction. N Engl J Med. 2024;391(14):1277-1286. doi:10.1056/NEJMoa2404204 · PMID 39213187C4C7G2G5I1
  338. Silvain J, Choi KH, Monguillon V, Kang D, Cayla G, Kim W, et al. Discontinuation of β-blockers in stable patients with previous myocardial infarction, preserved left ventricular ejection fraction, and no heart failure: a pooled analysis of individual patient data. Lancet. 2026;408(10560):1093-1102. doi:10.1016/S0140-6736(26)01426-1 · PMID 42669300C4C7G2G5I1
  339. Simader FA, Rajkumar CA, Foley MJ, Ahmed-Jushuf F, Chotai S, Bual N, et al. Symptoms as a Predictor of the Placebo-Controlled Efficacy of PCI in Stable Coronary Artery Disease. J Am Coll Cardiol. 2024;84(1):13-24. doi:10.1016/j.jacc.2024.04.016 · PMID 38759906C9
  340. Sinha A, Rahman H, Douiri A, Demir OM, De Silva K, Clapp B, et al. ChaMP-CMD: A Phenotype-Blinded, Randomized Controlled, Cross-Over Trial. Circulation. 2024;149(1):36-47. doi:10.1161/CIRCULATIONAHA.123.066680 · PMID 37905403G2H3I1
  341. Slipczuk L, Blankstein R, Bucciarelli-Ducci C, Braun LT, Phillips LM, Piña P, et al. State of the Art: Evaluation and Medical Management of Nonobstructive Coronary Artery Disease in Patients With Chest Pain: A Scientific Statement From the American Heart Association. Circulation. 2025;152(23):e443-e466. doi:10.1161/CIR.0000000000001394 · PMID 41208705G1H3
  342. Sonck J, Nagumo S, Norgaard BL, Otake H, Ko B, Zhang J, et al. Clinical Validation of a Virtual Planner for Coronary Interventions Based on Coronary CT Angiography. JACC Cardiovasc Imaging. 2022;15(7):1242-1255. doi:10.1016/j.jcmg.2022.02.003 · PMID 35798401C9
  343. Song L, Xu B, Tu S, Guan C, Jin Z, Yu B, et al. 2-Year Outcomes of Angiographic Quantitative Flow Ratio-Guided Coronary Interventions. J Am Coll Cardiol. 2022;80(22):2089-2101. doi:10.1016/j.jacc.2022.09.007 · PMID 36424680H5
  344. Sorbets E, Fox KM, Elbez Y, Danchin N, Dorian P, Ferrari R, et al. Long-term outcomes of chronic coronary syndrome worldwide: insights from the international CLARIFY registry. Eur Heart J. 2020;41(3):347-356. doi:10.1093/eurheartj/ehz660 · PMID 31504434B4G3
  345. Sotomi Y, Kozuma K, Higuchi Y, Nakazawa G, Morino Y, Ando K, et al. 1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial. Lancet. 2026;408(10553):440-452. doi:10.1016/S0140-6736(26)00665-3 · PMID 42456692C10G2
  346. Spertus JA, Jones PG, Maron DJ, O'Brien SM, Reynolds HR, Rosenberg Y, et al. Health-Status Outcomes with Invasive or Conservative Care in Coronary Disease. N Engl J Med. 2020;382(15):1408-1419. doi:10.1056/NEJMoa1916370 · PMID 32227753C9G2
  347. Stefanini GG, Alfonso F, Barbato E, Byrne RA, Capodanno D, Colleran R, et al. Management of myocardial revascularisation failure: an expert consensus document of the EAPCI. EuroIntervention. 2020;16(11):e875-e890. doi:10.4244/EIJ-D-20-00487 · PMID 32597391C9
  348. Steg PG, Greenlaw N, Tendera M, Tardif JC, Ferrari R, Al-Zaibag M, et al. Prevalence of anginal symptoms and myocardial ischemia and their effect on clinical outcomes in outpatients with stable coronary artery disease: data from the International Observational CLARIFY Registry. JAMA Intern Med. 2014;174(10):1651-9. doi:10.1001/jamainternmed.2014.3773 · PMID 25110899G3
  349. Steg PG, Bhatt DL, Simon T, Fox K, Mehta SR, Harrington RA, et al. Ticagrelor in Patients with Stable Coronary Disease and Diabetes. N Engl J Med. 2019;381(14):1309-1320. doi:10.1056/NEJMoa1908077 · PMID 31475798C10G2I1
  350. Stone GW, Kappetein AP, Sabik JF, Pocock SJ, Morice MC, Puskas J, et al. Five-Year Outcomes after PCI or CABG for Left Main Coronary Disease. N Engl J Med. 2019;381(19):1820-1830. doi:10.1056/NEJMoa1909406 · PMID 31562798C9G2
  351. Stone PH, Gratsiansky NA, Blokhin A, Huang IZ, Meng L, ERICA Investigators. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol. 2006;48(3):566-75. doi:10.1016/j.jacc.2006.05.044 · PMID 16875985C4G2I1
  352. Svanerud J, Ahn JM, Jeremias A, van 't Veer M, Gore A, Maehara A, et al. Validation of a novel non-hyperaemic index of coronary artery stenosis severity: the Resting Full-cycle Ratio (VALIDATE RFR) study. EuroIntervention. 2018;14(7):806-814. doi:10.4244/EIJ-D-18-00342 · PMID 29790478H5
  353. Sánchez Fernández JJ, Ruiz Ortiz M, Ogayar Luque C, Cantón Gálvez JM, Romo Peñas E, Mesa Rubio D, et al. Long-term Survival in a Spanish Population With Stable Ischemic Heart Disease. The CICCOR Registry. Rev Esp Cardiol (Engl Ed). 2019;72(10):827-834. doi:10.1016/j.rec.2018.08.019 · PMID 30268655G3
  354. Takagi Y, Takahashi J, Yasuda S, Miyata S, Tsunoda R, Ogata Y, et al. Prognostic stratification of patients with vasospastic angina: a comprehensive clinical risk score developed by the Japanese Coronary Spasm Association. J Am Coll Cardiol. 2013;62(13):1144-53. doi:10.1016/j.jacc.2013.07.018 · PMID 23916938H3
  355. Takahashi T, Samuels BA, Li W, Parikh MA, Wei J, Moses JW, et al. Safety of Provocative Testing With Intracoronary Acetylcholine and Implications for Standard Protocols. J Am Coll Cardiol. 2022;79(24):2367-2378. doi:10.1016/j.jacc.2022.03.385 · PMID 35710187H3
  356. Tapp DN, Kaur S, Toleva O, Tipler P, Ashokprabhu N, Acharya P, et al. Empagliflozin Improves Angina and Endothelial Dysfunction Indices in Angina and No Obstructive Coronary Arteries (ANOCA). Arterioscler Thromb Vasc Biol. 2026. doi:10.1161/ATVBAHA.126.324735 · PMID 42817877G5
  357. Tarantini G, Tang G, Nai Fovino L, Blackman D, Van Mieghem NM, Kim WK, et al. Management of coronary artery disease in patients undergoing transcatheter aortic valve implantation. A clinical consensus statement from the European Association of Percutaneous Cardiovascular Interventions in collaboration with the ESC Working Group on Cardiovascular Surgery. EuroIntervention. 2023;19(1):37-52. doi:10.4244/EIJ-D-22-00958 · PMID 36811935G1
  358. Tardif JC, Ford I, Tendera M, Bourassa MG, Fox K, INITIATIVE Investigators. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J. 2005;26(23):2529-36. doi:10.1093/eurheartj/ehi586 · PMID 16214830G2I1
  359. Tardif JC, Ponikowski P, Kahan T, ASSOCIATE Study Investigators. Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J. 2009;30(5):540-8. doi:10.1093/eurheartj/ehn571 · PMID 19136486I1
  360. Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N Engl J Med. 2019;381(26):2497-2505. doi:10.1056/NEJMoa1912388 · PMID 31733140C8I1
  361. Task Force Members, Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34(38):2949-3003. doi:10.1093/eurheartj/eht296 · PMID 23996286G1
  362. Testa L, De la Torre Hernandez JM, De Maria GL, Jones DA, Piñon-Esteban P, Campo G, et al. IVUS-Guided versus Angiography-Guided PCI in Unprotected Left Main Coronary Disease. N Engl J Med. 2026;394(22):2189-2199. doi:10.1056/NEJMoa2600440 · PMID 41911017C9G2
  363. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353(9146):9-13. doi:10.1016/S0140-6736(98)11181-9 · PMID 10023943I1
  364. Thuijs DJFM, Kappetein AP, Serruys PW, Mohr FW, Morice MC, Mack MJ, et al. Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial. Lancet. 2019;394(10206):1325-1334. doi:10.1016/S0140-6736(19)31997-X · PMID 31488373C9G2
  365. Tian J, Wang Z, Wang Y, Wang F, Peng X, Xiao J, et al. Extended Dual Antiplatelet Therapy for Multivessel Coronary Artery Disease. N Engl J Med. 2026;395(3):233-242. doi:10.1056/NEJMoa2517588 · PMID 42456136C10G2
  366. Tong DC, Quinn S, Nasis A, Hiew C, Roberts-Thomson P, Adams H, et al. Colchicine in Patients With Acute Coronary Syndrome: The Australian COPS Randomized Clinical Trial. Circulation. 2020;142(20):1890-1900. doi:10.1161/CIRCULATIONAHA.120.050771 · PMID 32862667I1
  367. Tonino PA, De Bruyne B, Pijls NH, Siebert U, Ikeno F, van' t Veer M, et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med. 2009;360(3):213-24. doi:10.1056/NEJMoa0807611 · PMID 19144937G2
  368. Tonino PA, Fearon WF, De Bruyne B, Oldroyd KG, Leesar MA, Ver Lee PN, et al. Angiographic versus functional severity of coronary artery stenoses in the FAME study fractional flow reserve versus angiography in multivessel evaluation. J Am Coll Cardiol. 2010;55(25):2816-21. doi:10.1016/j.jacc.2009.11.096 · PMID 20579537H1
  369. Toth G, Hamilos M, Pyxaras S, Mangiacapra F, Nelis O, De Vroey F, et al. Evolving concepts of angiogram: fractional flow reserve discordances in 4000 coronary stenoses. Eur Heart J. 2014;35(40):2831-8. doi:10.1093/eurheartj/ehu094 · PMID 24644308H1
  370. Tsarouchas A, Mutschlechner D, Tscharre M, Papadopoulos CE, Gremmel T. Oral Anticoagulant Monotherapy Versus Combination Therapy in Patients With Chronic Coronary Syndrome: A Systematic Review and Meta-analysis of Randomized Trials. Eur J Prev Cardiol. 2026. doi:10.1093/eurjpc/zwag416 · PMID 42576699G5
  371. Ulacia Flores P, Cieza T, Ouarrak S, Ruhl A, Mengi S, De Larochellière R, et al. Randomized Study Comparing Angiography Guidance With Physiology Guidance After PCI: The EASY-PREDICT Study. Circ Cardiovasc Interv. 2025;18(7):e015165. doi:10.1161/CIRCINTERVENTIONS.125.015165 · PMID 40400236G2G5
  372. Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. Eur Heart J. 2019;40(31):2632-2653. doi:10.1093/eurheartj/ehz372 · PMID 31116395C7C10H5
  373. Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39(3):213-260. doi:10.1093/eurheartj/ehx419 · PMID 28886622G1
  374. Valgimigli M, Frigoli E, Heg D, Tijssen J, Jüni P, Vranckx P, et al. Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk. N Engl J Med. 2021;385(18):1643-1655. doi:10.1056/NEJMoa2108749 · PMID 34449185C7C10G2
  375. Valgimigli M, Choi KH, Giacoppo D, Gragnano F, Kimura T, Watanabe H, et al. Clopidogrel versus aspirin for secondary prevention of coronary artery disease: a systematic review and individual patient data meta-analysis. Lancet. 2025;406(10508):1091-1102. doi:10.1016/S0140-6736(25)01562-4 · PMID 40902613C10G5I1
  376. Van Belle E, Rioufol G, Pouillot C, Cuisset T, Bougrini K, Teiger E, et al. Outcome impact of coronary revascularization strategy reclassification with fractional flow reserve at time of diagnostic angiography: insights from a large French multicenter fractional flow reserve registry. Circulation. 2014;129(2):173-85. doi:10.1161/CIRCULATIONAHA.113.006646 · PMID 24255062G3
  377. Van Belle E, Raposo L, Bravo Baptista S, Vincent F, Porouchani S, Cosenza A, et al. Impact of an Interactive CT/FFR(CT) Interventional Planner on Coronary Artery Disease Management Decision Making. JACC Cardiovasc Imaging. 2021;14(5):1068-1070. doi:10.1016/j.jcmg.2020.09.040 · PMID 33454253C9
  378. van der Does R, Hauf-Zachariou U, Pfarr E, Holtbrügge W, König S, Griffiths M, et al. Comparison of safety and efficacy of carvedilol and metoprolol in stable angina pectoris. Am J Cardiol. 1999;83(5):643-9. doi:10.1016/s0002-9149(98)00960-6 · PMID 10080412I1
  379. Van Gelder IC, Rienstra M, Bunting KV, Casado-Arroyo R, Caso V, Crijns HJGM, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024;45(36):3314-3414. doi:10.1093/eurheartj/ehae176 · PMID 39210723C6C10G1I1
  380. Varenne O, Cook S, Sideris G, Kedev S, Cuisset T, Carrié D, et al. Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial. Lancet. 2018;391(10115):41-50. doi:10.1016/S0140-6736(17)32713-7 · PMID 29102362C6G2
  381. Velazquez EJ, Lee KL, Deja MA, Jain A, Sopko G, Marchenko A, et al. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med. 2011;364(17):1607-16. doi:10.1056/NEJMoa1100356 · PMID 21463150C9G2
  382. Velazquez EJ, Lee KL, Jones RH, Al-Khalidi HR, Hill JA, Panza JA, et al. Coronary-Artery Bypass Surgery in Patients with Ischemic Cardiomyopathy. N Engl J Med. 2016;374(16):1511-20. doi:10.1056/NEJMoa1602001 · PMID 27040723C9G2
  383. Verheye S, Jolicœur EM, Behan MW, Pettersson T, Sainsbury P, Hill J, et al. Efficacy of a device to narrow the coronary sinus in refractory angina. N Engl J Med. 2015;372(6):519-27. doi:10.1056/NEJMoa1402556 · PMID 25651246C9G2
  384. Verheye S, van de Hoef TP, de Silva R, van Kuijk JP, Byrne J, Montorfano M, et al. Coronary Sinus Narrowing for Treating Refractory Angina: REDUCER-I Multicenter "Real-World" Observational Study Primary Endpoint Analysis. JACC Cardiovasc Interv. 2024;17(24):2908-2918. doi:10.1016/j.jcin.2024.08.047 · PMID 39520437G5
  385. Vidal-Perez R, Otero-Raviña F, Franco M, Rodríguez Garcia JM, Liñares Stolle R, Esteban Alvarez R, et al. Determinants of cardiovascular mortality in a cohort of primary care patients with chronic ischemic heart disease. BARBANZA Ischemic Heart Disease (BARIHD) study. Int J Cardiol. 2013;167(2):442-50. doi:10.1016/j.ijcard.2012.01.014 · PMID 22305776G3
  386. Vink CEM, Woudstra J, Lee JM, Boerhout CKM, Cook CM, Hoshino M, et al. Sex differences in prevalence and outcomes of the different endotypes of chronic coronary syndrome in symptomatic patients undergoing invasive coronary angiography: Insights from the global ILIAS invasive coronary physiology registry. Atherosclerosis. 2023;384:117167. doi:10.1016/j.atherosclerosis.2023.06.073 · PMID 37558604G3
  387. Virani SS, Newby LK, Arnold SV, Bittner V, Brewer LC, Demeter SH, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2023;148(9):e9-e119. doi:10.1161/CIR.0000000000001168 · PMID 37471501B4C7G1H5
  388. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-3337. doi:10.1093/eurheartj/ehab484 · PMID 34458905G1I1
  389. Vivas D, Ferrandis R, Anguita-Sánchez M, Anguita-Gámez M, Arcelus JI, Echeverri M, et al. Perioperative and periprocedural management of antithrombotic therapy: 2025 consensus document of SEC, SEDAR, SEACV, SECCE, AEC, SECOM CYC, SECPRE, SEPD, SEGG, SEGO, SEHH, SETH, SEMERGEN, SEMFYC, SEMG, SEMICYUC, SEMI, SEMES, SEN, S.E.N., SENEC, SEPAR, SEO, SEORL-CCC, SEPA, SERVEI, SECOT, and AEU. Rev Esp Cardiol (Engl Ed). 2026;79(1):68-79. doi:10.1016/j.rec.2025.09.003 · PMID 40983168C6C10G1
  390. von Arnim T. Medical treatment to reduce total ischemic burden: total ischemic burden bisoprolol study (TIBBS), a multicenter trial comparing bisoprolol and nifedipine. The TIBBS Investigators. J Am Coll Cardiol. 1995;25(1):231-8. doi:10.1016/0735-1097(94)00345-q · PMID 7798508I1
  391. Von Arnim T. Prognostic significance of transient ischemic episodes: response to treatment shows improved prognosis. Results of the Total Ischemic Burden Bisoprolol Study (TIBBs) follow-up. J Am Coll Cardiol. 1996;28(1):20-4. doi:10.1016/0735-1097(96)00122-2 · PMID 8752790I1
  392. Vranckx P, Valgimigli M, Jüni P, Hamm C, Steg PG, Heg D, et al. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet. 2018;392(10151):940-949. doi:10.1016/S0140-6736(18)31858-0 · PMID 30166073I1
  393. Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J, et al. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024;45(36):3415-3537. doi:10.1093/eurheartj/ehae177 · PMID 39210710B1B4B6C1C2C3C4C5C6C7C8C9C10D1D3D4E3G1G5H1H3H4H5I1I2
  394. Walker JM, Curry PV, Bailey AE, Steare SE. A comparison of nifedipine once daily, isosorbide mononitrate once daily, and isosorbide dinitrate twice daily in patients with chronic stable angina. Int J Cardiol. 1996;53(2):117-26. doi:10.1016/0167-5273(95)02531-6 · PMID 8682597I1
  395. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045-57. doi:10.1056/NEJMoa0904327 · PMID 19717846I1
  396. Wang Y, Zhu S, Gao P, Zhang Q. Comparison of coronary artery bypass grafting and drug-eluting stents in patients with chronic kidney disease and multivessel disease: A meta-analysis. Eur J Intern Med. 2017;43:28-35. doi:10.1016/j.ejim.2017.04.002 · PMID 28400078C6
  397. Watanabe H, Ozasa N, Morimoto T, Shiomi H, Bingyuan B, Suwa S, et al. Long-term use of carvedilol in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. PLoS One. 2018;13(8):e0199347. doi:10.1371/journal.pone.0199347 · PMID 30153268I1
  398. Weir-McCall JR, Koweek L, Suchá D, Nørgaard BL, Curzen N, Fairbairn TA, et al. Fractional flow reserve in coronary computed tomography angiography: An expert consensus document of the society of cardiovascular computed tomography (SCCT) and the society for cardiovascular angiography and interventions (SCAI). Endorsed by the American college of cardiology (ACC). J Cardiovasc Comput Tomogr. 2026;20(4):316-332. doi:10.1016/j.jcct.2026.05.006 · PMID 42236373G1
  399. Weiss R, Ferry D, Pickering E, Smith LK, Dennish G 3rd, Krug-Gourley S, et al. Effectiveness of three different doses of carvedilol for exertional angina. Carvedilol-Angina Study Group. Am J Cardiol. 1998;82(8):927-31. doi:10.1016/s0002-9149(98)00507-4 · PMID 9794346I1
  400. Weisz G, Généreux P, Iñiguez A, Zurakowski A, Shechter M, Alexander KP, et al. Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2016;387(10014):136-45. doi:10.1016/S0140-6736(15)00459-6 · PMID 26474810C4G2I1
  401. Werner GS, Martin-Yuste V, Hildick-Smith D, Boudou N, Sianos G, Gelev V, et al. A randomized multicentre trial to compare revascularization with optimal medical therapy for the treatment of chronic total coronary occlusions. Eur Heart J. 2018;39(26):2484-2493. doi:10.1093/eurheartj/ehy220 · PMID 29722796C9G2
  402. Werner GS, Kim JH, Hildick-Smith D, Kang DY, Yuste VM, Ahn JM, et al. Quality of Life After Percutaneous Coronary Intervention or Medical Therapy for Chronic Total Coronary Occlusions: EUROCTO and DECISION-CTO Meta-Analysis. J Am Coll Cardiol. 2026;88(1):24-37. doi:10.1016/j.jacc.2026.02.5099 · PMID 41949523C9
  403. Wille F, Wille ME, Zuidema X, Hollmann MW, Bieze M, Kallewaard JW. Burst Spinal Cord Stimulation for Refractory Angina Pectoris: A Prospective Pilot Study-The BAP Study. Neuromodulation. 2026;29(6):988-995. doi:10.1016/j.neurom.2026.03.013 · PMID 42171550G5
  404. Williams MC, Moss AJ, Dweck M, Adamson PD, Alam S, Hunter A, et al. Coronary Artery Plaque Characteristics Associated With Adverse Outcomes in the SCOT-HEART Study. J Am Coll Cardiol. 2019;73(3):291-301. doi:10.1016/j.jacc.2018.10.066 · PMID 30678759H1
  405. Williams MC, Kwiecinski J, Doris M, McElhinney P, D'Souza MS, Cadet S, et al. Low-Attenuation Noncalcified Plaque on Coronary Computed Tomography Angiography Predicts Myocardial Infarction: Results From the Multicenter SCOT-HEART Trial (Scottish Computed Tomography of the HEART). Circulation. 2020;141(18):1452-1462. doi:10.1161/CIRCULATIONAHA.119.044720 · PMID 32174130H1
  406. Williams MC, Wereski R, Tuck C, Adamson PD, Shah ASV, van Beek EJR, et al. Coronary CT angiography-guided management of patients with stable chest pain: 10-year outcomes from the SCOT-HEART randomised controlled trial in Scotland. Lancet. 2025;405(10475):329-337. doi:10.1016/S0140-6736(24)02679-5 · PMID 39863372G2
  407. Williams MS, Levine GN, Kalra D, Agarwala A, Baptiste D, Cigarroa JE, et al. 2025 AHA/ACC Clinical Performance and Quality Measures for Patients With Chronic Coronary Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Performance Measures. J Am Coll Cardiol. 2025;85(25):2504-2535. doi:10.1016/j.jacc.2025.02.001 · PMID 40310322G1
  408. Wilson SR, Scirica BM, Braunwald E, Murphy SA, Karwatowska-Prokopczuk E, Buros JL, et al. Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial. J Am Coll Cardiol. 2009;53(17):1510-6. doi:10.1016/j.jacc.2009.01.037 · PMID 19389561I1
  409. Winther S, Schmidt SE, Mayrhofer T, Bøtker HE, Hoffmann U, Douglas PS, et al. Incorporating Coronary Calcification Into Pre-Test Assessment of the Likelihood of Coronary Artery Disease. J Am Coll Cardiol. 2020;76(21):2421-2432. doi:10.1016/j.jacc.2020.09.585 · PMID 33213720C5H4
  410. Winther S, Schmidt SE, Foldyna B, Mayrhofer T, Rasmussen LD, Dahl JN, et al. Coronary Calcium Scoring Improves Risk Prediction in Patients With Suspected Obstructive Coronary Artery Disease. J Am Coll Cardiol. 2022;80(21):1965-1977. doi:10.1016/j.jacc.2022.08.805 · PMID 36396197C5
  411. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001-15. doi:10.1056/NEJMoa0706482 · PMID 17982182I1
  412. Wood DA, Jennings CS, Kotseva K, Adamska A, Erlund I, Ganly S, et al. ESC Guidelines on prevention and rehabilitation in coronary heart disease and current practice: the EUROASPIRE VI survey. Eur Heart J. 2026. doi:10.1093/eurheartj/ehag741 · PMID 42666091G3
  413. Writing Committee Members, Virani SS, Newby LK, Arnold SV, Bittner V, Brewer LC, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2023;82(9):833-955. doi:10.1016/j.jacc.2023.04.003 · PMID 37480922G1I1
  414. Writing Committee Members, Blumenthal RS, Morris PB, Gaudino M, Johnson HM, Anderson TS, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2026;153(17):e1154-e1276. doi:10.1161/CIR.0000000000001423 · PMID 41824552C5C7
  415. Xaplanteris P, Fournier S, Pijls NHJ, Fearon WF, Barbato E, Tonino PAL, et al. Five-Year Outcomes with PCI Guided by Fractional Flow Reserve. N Engl J Med. 2018;379(3):250-259. doi:10.1056/NEJMoa1803538 · PMID 29785878C9G2
  416. Xu B, Tu S, Song L, Jin Z, Yu B, Fu G, et al. Angiographic quantitative flow ratio-guided coronary intervention (FAVOR III China): a multicentre, randomised, sham-controlled trial. Lancet. 2021;398(10317):2149-2159. doi:10.1016/S0140-6736(21)02248-0 · PMID 34742368G2
  417. Yasuda S, Kaikita K, Akao M, Ako J, Matoba T, Nakamura M, et al. Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease. N Engl J Med. 2019;381(12):1103-1113. doi:10.1056/NEJMoa1904143 · PMID 31475793C10G2I1
  418. Yndigegn T, Lindahl B, Mars K, Alfredsson J, Benatar J, Brandin L, et al. Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction. N Engl J Med. 2024;390(15):1372-1381. doi:10.1056/NEJMoa2401479 · PMID 38587241C4C7G5
  419. Yuan X, Li J, Lei L, Zhang L, Chen K, Chu Q, et al. Efficacy of dual antiplatelet therapy for three months versus 12 months after coronary artery bypass grafting: multicentre, double blinded, randomised controlled trial. BMJ. 2026;393:e088939. doi:10.1136/bmj-2025-088939 · PMID 42120081C10G2
  420. Zamorano JL, García-Moll X, Ferrari R, Greenlaw N. Demographic and clinical characteristics of patients with stable coronary artery disease: results from the CLARIFY registry in Spain. Rev Esp Cardiol (Engl Ed). 2014;67(7):538-44. doi:10.1016/j.rec.2013.10.020 · PMID 24952393G3
  421. Zannad F, Anker SD, Byra WM, Cleland JGF, Fu M, Gheorghiade M, et al. Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease. N Engl J Med. 2018;379(14):1332-1342. doi:10.1056/NEJMoa1808848 · PMID 30146935I1
  422. Zeppenfeld K, Tfelt-Hansen J, de Riva M, Winkel BG, Behr ER, Blom NA, et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022;43(40):3997-4126. doi:10.1093/eurheartj/ehac262 · PMID 36017572C7H3
  423. Zhu Y, Zhang W, Dimagli A, Han L, Cheng Z, Mei J, et al. Antiplatelet therapy after coronary artery bypass surgery: five year follow-up of randomised DACAB trial. BMJ. 2024;385:e075707. doi:10.1136/bmj-2023-075707 · PMID 38862179C10G2
  424. Zolnierek KB, Dimatteo MR. Physician communication and patient adherence to treatment: a meta-analysis. Med Care. 2009;47(8):826-34. doi:10.1097/MLR.0b013e31819a5acc · PMID 19584762C8

Otros documentos con DOI (2)

  1. Comentarios a la guía ESC 2024 sobre el diagnóstico y el tratamiento de los síndromes coronarios crónicos. Revista Española de Cardiología. 2025;78(3):170-175. doi:10.1016/j.recesp.2024.10.009G1
  2. Monguió Santín E, Martín Gutiérrez E, Cuerpo Caballero G, Centella Hernández T, Polo López L, García Fuster R, et al. Cirugía cardiovascular en España en el año 2024. Registro de intervenciones de la Sociedad Española de Cirugía Cardiovascular y Endovascular. Cirugía Cardiovascular. 2026;33(3):150-164. doi:10.1016/j.circv.2026.02.002C7H2

Fichas técnicas (CIMA, AEMPS) (112)

  1. Ficha técnica de amlodipino. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 59159C1C3C4C7D4I1I2
  2. Ficha técnica de amlodipino. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 59162H3I2
  3. Ficha técnica de amlodipino. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 65460I2
  4. Ficha técnica de apixabán. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 111691009C10
  5. Ficha técnica de atenolol. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 55529C3C4C7H3I1I2
  6. Ficha técnica de atenolol. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 56967C3I1I2
  7. Ficha técnica de atenolol. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 63147C3I2
  8. Ficha técnica de atorvastatina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 74684C3I2
  9. Ficha técnica de avanafilo. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 113841004C4D4I2
  10. Ficha técnica de bisoprolol. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 57654C3C4C7D4H3I2
  11. Ficha técnica de bisoprolol. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 57655I1I2
  12. Ficha técnica de bisoprolol. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 63046I2
  13. Ficha técnica de bisoprolol. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 63048I2
  14. Ficha técnica de bisoprolol. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 78903C3I1I2
  15. Ficha técnica de cafeína y ergotamina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 17558H3
  16. Ficha técnica de cafeína y nitroglicerina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 35534C3C4D4I2
  17. Ficha técnica de carvedilol. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 59695C3C4C7I1I2
  18. Ficha técnica de carvedilol. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 61281C3H3I2
  19. Ficha técnica de carvedilol. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 68328I2
  20. Ficha técnica de clopidogrel. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 71622C3I2
  21. Ficha técnica de clopidogrel. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 98069001C1C3I2
  22. Ficha técnica de clopidogrel. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 98069009C3I2
  23. Ficha técnica de clopidogrel. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 98070001C3C10I1I2
  24. Ficha técnica de colchicina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 33720I2
  25. Ficha técnica de colchicina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 78947I1I2
  26. Ficha técnica de colchicina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 90154I2
  27. Ficha técnica de dabigatrán. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 08442011C10
  28. Ficha técnica de digoxina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 34566C3I2
  29. Ficha técnica de diltiazem. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 55285C3H3I1I2
  30. Ficha técnica de diltiazem. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 58483C3I2
  31. Ficha técnica de diltiazem. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 59911C3I2
  32. Ficha técnica de diltiazem. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 60006C3I2
  33. Ficha técnica de diltiazem. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 60200I2
  34. Ficha técnica de diltiazem. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 60217C3C4C7D4H3I1I2
  35. Ficha técnica de diltiazem. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 60231C3I2
  36. Ficha técnica de diltiazem. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 60740C3I2
  37. Ficha técnica de diltiazem. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 60820C3I2
  38. Ficha técnica de diltiazem. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 61132I2
  39. Ficha técnica de edoxabán. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 115993018C10
  40. Ficha técnica de ezetimiba y simvastatina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 66513C3I2
  41. Ficha técnica de felodipino. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 59269C3I1I2
  42. Ficha técnica de felodipino. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 64832C3I2
  43. Ficha técnica de ivabradina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 05316003I2
  44. Ficha técnica de ivabradina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 05317003C1C3C4C7D4I1I2
  45. Ficha técnica de ivabradina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 81279C3I2
  46. Ficha técnica de ivabradina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 82514I2
  47. Ficha técnica de lercanidipino. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 61653C3C7I2
  48. Ficha técnica de lercanidipino. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 65379C3I2
  49. Ficha técnica de lercanidipino. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 71633C3I2
  50. Ficha técnica de metilergometrina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 25658H3
  51. Ficha técnica de metoprolol. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 54503C3C4C7I1I2
  52. Ficha técnica de metoprolol. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 56989I2
  53. Ficha técnica de metoprolol. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 82000C3H3I1I2
  54. Ficha técnica de mononitrato de isosorbida. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 56945C3I2
  55. Ficha técnica de mononitrato de isosorbida. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 56946C3C4D4I1I2
  56. Ficha técnica de mononitrato de isosorbida. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 58078C3I2
  57. Ficha técnica de mononitrato de isosorbida. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 58635C3I2
  58. Ficha técnica de mononitrato de isosorbida. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 59357C3H3I2
  59. Ficha técnica de nebivolol. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 61428C1C3C4C7I1I2
  60. Ficha técnica de nebivolol. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 73926I2
  61. Ficha técnica de nebivolol. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 83604H3I2
  62. Ficha técnica de nifedipino. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 59538C3H3I1I2
  63. Ficha técnica de nitroglicerina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 55768C3C4C7D4I1I2
  64. Ficha técnica de nitroglicerina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 56574C3C4C7D4I2
  65. Ficha técnica de nitroglicerina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 57127I2
  66. Ficha técnica de nitroglicerina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 57359C3C4D4I2
  67. Ficha técnica de nitroglicerina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 58567C3I2
  68. Ficha técnica de nitroglicerina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 59989I2
  69. Ficha técnica de nitroglicerina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 61696C3I2
  70. Ficha técnica de nitroglicerina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 63677I2
  71. Ficha técnica de nitroglicerina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 71210I2
  72. Ficha técnica de prasugrel. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 08503002I2
  73. Ficha técnica de prasugrel. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 08503009C1C3C10I1I2
  74. Ficha técnica de prasugrel. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 82929I2
  75. Ficha técnica de ranolazina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 08462001C1C3C4C7D4I1I2
  76. Ficha técnica de ranolazina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 88005C3I2
  77. Ficha técnica de riociguat. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 113907004C4D4I2
  78. Ficha técnica de rivaroxabán. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 08472018C10
  79. Ficha técnica de rivaroxabán. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 108472027C1C3C10I1I2
  80. Ficha técnica de rivaroxabán. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 86415C3I2
  81. Ficha técnica de rizatriptán. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 62291H3
  82. Ficha técnica de sildenafilo. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 05318001I2
  83. Ficha técnica de sildenafilo. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 74008I2
  84. Ficha técnica de sildenafilo. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 82833I2
  85. Ficha técnica de simvastatina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 58846C3I2
  86. Ficha técnica de simvastatina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 65199C3I2
  87. Ficha técnica de sumatriptán. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 66406H3
  88. Ficha técnica de tadalafilo. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 02237001C4D4I2
  89. Ficha técnica de tadalafilo. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 02237008I2
  90. Ficha técnica de tadalafilo. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 08476006I2
  91. Ficha técnica de tadalafilo. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 84402I2
  92. Ficha técnica de ticagrelor. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 10655004C1C3D4I2
  93. Ficha técnica de ticagrelor. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 110655009C3C10I1I2
  94. Ficha técnica de ticagrelor. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 89558I2
  95. Ficha técnica de trimetazidina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 56704C1C3I1I2
  96. Ficha técnica de trimetazidina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 68228C3C4C7D4I2
  97. Ficha técnica de vardenafilo. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 82923I2
  98. Ficha técnica de verapamilo. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 39784I2
  99. Ficha técnica de verapamilo. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 50891C1C3I1I2
  100. Ficha técnica de verapamilo. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 53434C3I2
  101. Ficha técnica de verapamilo. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 58369C3I2
  102. Ficha técnica de verapamilo. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 60724C3C4D4H3I1I2
  103. Ficha técnica de vericiguat. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 1211561023C4D4I2
  104. Ficha técnica de zolmitriptán. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 74385H3
  105. Ficha técnica de ácido acetilsalicílico. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 40498C3I2
  106. Ficha técnica de ácido acetilsalicílico. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 42991C3D4I2
  107. Ficha técnica de ácido acetilsalicílico. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 58791C3I2
  108. Ficha técnica de ácido acetilsalicílico. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 59210C3I2
  109. Ficha técnica de ácido acetilsalicílico. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 62825C3I2
  110. Ficha técnica de ácido acetilsalicílico. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 78184C3I2
  111. Ficha técnica de ácido acetilsalicílico. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 81216C3C10I1I2
  112. Ficha técnica de ácido acetilsalicílico. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 11/11/2026. CIMA, registro 81793C3I2
La lista se hace sola con lo que citan las páginas de este ESPACIO (PubMed por el PMID; el DOI, en PubMed o en Crossref; las fichas técnicas, en CIMA; los estudios en marcha, en ClinicalTrials.gov) y se rehace cada vez que se actualiza el ESPACIO; seis autores y «et al.», como pide el estilo Vancouver.

ESPACIO formativo de CardioTeca.com sobre síndrome coronario crónico. Contenidos elaborados con independencia editorial y dirigidos a profesionales sanitarios. Los fármacos se nombran por su denominación común internacional. Edita y revisa el Comité Editorial de CardioTeca. Última actualización: .

Comité científico · Independencia editorial · Preguntas sobre el ESPACIO

Cuenta gratuitapara profesionales sanitarios

Únete a la comunidad CardioTeca

Ya somos más de 27.000 profesionales. Crear tu cuenta te lleva un par de minutos.

Ejemplo de página profesional en CardioTeca
  • Accede sin límites a todos los contenidos y servicios de CardioTeca.
  • Tu página profesional, con tu foto, tus servicios, currículum, web y pedir cita.
  • Medicamentos, guías interactivas y calculadoras para el día a día.
  • Recibe en tu mail casos clínicos, comentarios de expertos y todas las novedades.
Ejemplo de página profesional en CardioTeca
Crear mi cuenta gratis ¿Ya tienes cuenta? Inicia sesión

Actualidad

Formación

CardioTeca

Legal

La información que figura en CardioTeca.com está dirigida exclusivamente al profesional sanitario facultado para prescribir o dispensar medicamentos, por lo que se requiere una formación especializada para su correcta interpretación. El acceso a algunas secciones se realiza mediante contraseña, y sólo está disponible para profesionales sanitarios. Aunque el sitio web CardioTeca.com está dirigido a profesionales de la salud, la información médica visible en su área pública es de libre acceso. Por ello, queremos aclarar que el uso de estos contenidos por parte de la población no reemplaza en ningún momento la relación entre el médico y el paciente. Para obtener información específica sobre un caso concreto consulte siempre a su médico. En CardioTeca.com empleamos inteligencia artificial como herramienta de apoyo editorial, bajo supervisión de nuestro equipo médico.